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1. Introduction 
1.1 Cancer 
As reported by the World Health Organization (WHO) 8.8 million people died 
from cancer worldwide in 2015 and thus cancer is the second leading cause of 
death after cardiovascular diseases. The incidence of cancer rose from 12.7 
million in 2008 to 14.1 million in 2012. It is presumed that the number of new 
cases will increase by more than 70% in the upcoming 2 decades, bringing the 
number of cancer cases close to 25 million [1]. 
Cancer is a disease caused by different genetic abnormalities, like gene 
mutations or chromosomal changes, which result in loss of function in tumor-
suppressor genes or gain of function in oncogenes [2]. Furthermore, also 
epigenetic alterations have been considered as being causative for the onset of 
cancer [3].  
The routine treatments of cancer are surgery, chemotherapy and radiotherapy, 
which can be used in a single or combined application. There are further 
treatment options for different cancer entities available, such as immunotherapy 
or hormonal therapy.  
The development of new therapy options for cancer is an important and also 
necessary task of current medical research. Depending on the type of cancer, 
therapy options are often quite limited; thus it is indispensable to search for new 
therapy options, which have a better efficacy, an improved selectivity towards 
malignancies, good safety aspects and less adverse effects, respectively.  
Virotherapy represents a promising new strategy for human cancer therapy. 
Oncolytic viruses are capable of infecting selectively cancer cells, leading to cell 
death while normal cells remain undamaged [4]. Oncolysis describes the lysis 
or breakdown of cells caused by chemical or physical action, in this case, viral 
replication within cancer cells. Consequently, the great production of virus 
progeny leads to cell lysis and viral spread, thereby rolling out a wave of new 
infection rounds into neighboring, hitherto uninfected cancer cells (Figure 2). 
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Figure 1. Cancer related deaths in 2012 worldwide in both sexes combined. Data based on 
the WHO world cancer report 2014 [1]. 
 
1.1.1 Colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer and third leading 
cause of cancer-related death among men and women, with a continuous 
increase in incidence after the age of 50 [5]. Predisposing factors are colorectal 
adenomas, family history with a first-degree relative, hereditary syndromes, 
such as familial adenomatous polyposis (100% risk by age of 40) or hereditary 
nonpolyposis colorectal cancer (80% progress to CRC), inflammatory bowel 
diseases for example ulcerative colitis or Crohn’s disease. Dietary factors and 
lifestyle also play an important role. Among the risk factors for colorectal cancer 
are smoking, alcohol consumption and obesity [6, 7]. 
The preferred treatment option is the surgical resection of colorectal cancers 
and their metastases. The resection is complemented by adjuvant chemo-
therapy. Biologicals, such as anti-VEGF (vascular endothelial growth factor) 
antibodies or anti-EGFR (epidermal growth factor receptor) antibodies can be 
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added to the chemotherapy for metastatic disease [8, 9]. According to the 
American cancer society, the average 5-year-survival rate between 2007 and 
2013 was 64.9%, depending on the stage of cancer (American Cancer Society. 
Colorectal Cancer Facts & Figures 2017-2019). 
 
1.1.2 Renal cell adenocarcinoma 
Renal cell adenocarcinoma (RCC) is the most common cause for renal 
malignancies in adults. About 4 % are associated with hereditary disorders, but 
most of the cases are sporadic. Important risk factors include smoking, renal 
pelvic stones, acquired cystic disease of the kidney, obesity, hypertension and 
exposure to certain toxins, such as cadmium. The treatment of choice is the 
surgical resection of the tumor and metastases. The majority of small RCC can 
be cured by surgical resection [10]. RCCs are infamously resistant to chemo-
therapeutic agents. This is due to the fact that tumor cells express MDR-1 
(multidrug resistance protein-1). Thus, immunomodulatory or targeted therapy, 
e.g. Interferon-a, recombinant cytokines (interleukin-2), or tyrosine kinase 
inhibitors (sorafenib, sunitinib, pazopanib), are the treatment options for the 
metastatic disease [11]. The relative 5-year-survival rate is between 65 and 
75%, depending on the histological subtype [12].  
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1.2 Oncolytic virotherapy 
 
Figure 2. Oncolytic mechanism of virotherapeutics. The virus replicates selectively in 
cancer cells, then the virus progeny is released from the dying cancer cell and spreads and 
infects neighboring cancer cells while healthy cells remain undamaged. Figure taken from [13]. 
Starting in the 19th century, spontaneous tumor regression was observed after 
natural virus infections, mainly described in hematological diseases, such as 
leukemia and lymphomas [14, 15]. Further tumor regression was induced by 
viral vaccines, for instance smallpox and measles virus vaccination [16, 17].  
Some of the oncolytic viruses, for example reovirus [18], Newcastle disease 
virus [19] and vesicular stomatitis virus [20] exhibit a natural tumor selectivity 
and at the same point aren’t pathogenic or only lead to minor symptoms after 
infection in humans, since they are not the main host organism [21]. 
Furthermore, the human pathogen measles virus, which also has a natural 
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tumor selectivity was attenuated to be used as an oncolytic virus [22]. Lately, 
improvements in the field of virotherapy led to a better understanding of the 
mechanism of action of oncolytic virotherapy (OV).  
Besides wild-type virus strains, genetically engineered oncolytic viruses were 
produced improving tumor selectivity, efficacy, safety aspects, and attenuating 
side effects. These engineered viruses also entered clinical trials [23]. The aim 
could be a perfectly fitting oncolytic virotherapeutic that addresses a specific 
tumor biology. By modification of vectors, which encode specific functional 
transgenes, virotherapy holds great promise in the future of cancer therapy. 
 
1.2.1 Mechanisms of oncolytic virotherapy 
To deliver the virotherapeutic into cancer patients, different routes of application 
can be used, e.g. intratumoral, intravenous, intrapleural or intraperitoneal. 
Nevertheless, systemic delivery is the preferred approach for treatment of 
metastases or inaccessible tumors since it offers access to all vascularized 
tumor sites, while healthy cells remain intact [24]. Oncolytic viruses exploit 
deregulated processes in malignant cells, such as a defective antiviral response 
[25]. However, oncolytic viruses require specific alterations in the host cell 
signaling pathways, for example mutations within the interferon (IFN) mediated 
pathway. IFNs protect cells against viral infections, restrain cell proliferation, 
regulate the expression of specific genes and trigger apoptosis [26]. Malignant 
cells often are resistant towards IFN signals and thus protect themselves 
against elimination [27]. Meanwhile, cancer cells become sensitive to viral 
infection when they lose their innate antiviral protection, such as the IFN path-
way. This is one reason for the cancer selectivity of oncolytic viruses [28, 29]. 
Furthermore, tumor cells are attacked by different immune cells, first dendritic 
cells, which detect viral antigens, then CD8+ T and NK cells are recruited and 
activated by the infected tumor cells and viral particles [30, 31].  
Indeed, the activation of the adaptive immune system is an essential response 
to virotherapeutics, since tumor bearing mice, which had a lack of CD8+ T or 
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NK cells and were treated with oncolytic vesicular stomatitis viruses (VSV) 
showed lower oncolytic efficacy compared to fully immune competent mice [20]. 
 
1.2.2 Advantages and disadvantages 
Oncolytic viruses are capable of selectively replicating within tumor cells, 
leading to infection-related cell lysis by viral spread or apoptosis while normal 
cells remain undamaged [23].  
Even if chemotherapy or radiotherapy is non-effective, viruses are still able to 
kill tumor cells since there is no cross-resistance [32, 33]. Furthermore, tumor 
stem cells that are barely affected by chemotherapeutics, on the contrary show 
sensibility towards virotherapeutics [34, 35]. 
Also safety aspects were proved in various clinical trials for minimum six 
different virus species [23, 36] that mainly didn’t cause more than flu-like 
symptoms [23, 37].  
Despite these promising results, the immune system is able to recognize the 
virus as foreign and combats the viral particles often before they are able to 
efficiently infect tumor cells [32]. Already low antibody titers can neutralize the 
viruses [38]. Consequently, recurrent applications induce rising titers of 
neutralizing antibodies and decrease the oncolytic reaction [39]. Intratumoral 
application sometimes does not show any benefit either [40].  
Plenty of viruses were tested in clinical trials for the treatment of different solid 
tumors [40]. Unfortunately, some trials have shown that a monotherapy might 
not be sufficient to destroy tumor cells. Therefore, virotherapeutics were 
combined with different compounds, such as chemotherapeutics [41], radio-
therapy [42] and epigenetically modulating agents [43, 44] to enhance the 
therapeutical oncolysis [23, 45].  
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1.2.3 Vaccinia Virus 
Until the WHO defined smallpox as eradicated (1980), it was a dangerous 
infectious disease caused by variola virus. Smallpox has a high contagion 
potential since transmission occurs through airborne inhalation. After an 
incubation period of about 12 days flu-like symptoms, like fever or shivering, 
appear. After 3 - 4 days, characteristic red skin spots, so called enanthema 
occur, enlarge, rupture, and thus huge amounts of virus are released [46]. 
About 100 years ago, Edward Jenner noticed that people who caught cowpox 
didn’t catch smallpox, hence they were protected from variola infection [47]. 
Consequently, the vaccination of humans against smallpox started. In 1967, the 
WHO made a worldwide obligation to vaccinate. The last known smallpox 
infection occurred in 1977 in Somalia [48].  
Vaccinia virus (VACV) was originally isolated from infected cows, indeed later 
was mixed with isolates from horses to increase the potency [46]. At some 
point, these vaccines were replaced by another VACV, which is another pox-
virus whose origin remains unknown [49].  
Variola virus and vaccinia virus both belong to the Orthopoxvirinae into the 
biological family of Chordopoxvirinae. As a result of its usage as a vaccine for 
years, the tolerability and health effects could be characterized in detail [50]. 
The poxvirus is the largest known virus. The large double-stranded DNA 
(deoxyribonucleic acid) genome offers a variety of therapeutic and diagnostic 
possibilities as it allows the insertion of transgenes up to a size of 25 kb [51]. An 
enhanced tumor tissue tropism is induced by selective deletion of important 
genes, such as the depletion of thymidine kinase [52, 53]. Thymidine kinase is 
necessary for the viral infection of healthy cells, but it is not necessary for tumor 
cells. Thus, a thymidine kinase-deleted vaccinia virus mutant has the ability to 
replicate in and destroy selectively tumor cells [54]. 
VACV consists of distinct antigenic forms, such as an enveloped virus (EEV) 
form that envelopes itself in a host cell membrane that contains different 
complement control factors of the host’s immune system and several exposed 
viral proteins. Consequently, vaccinia virus can easily escape the immune 
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system and spread within the host’s bloodstream to reach distant tumors [55]. A 
systemic delivery of VACV is highly efficient [56, 57].  
Poxviruses are exclusive among DNA viruses, because replication only occurs 
within the cytoplasm of the cell in so called viral factories. Thus, VACV does not 
integrate into the host genome, which is a further important safety aspect [58]. 
Since VACV has been used as a smallpox vaccine, its safety in humans as well 
as side effects are well-documented [59]. In case of unexpected side effects 
after VACV application, different antiviral agents are available, such as 
Cidofovir, ST-246 or specific tyrosine kinase inhibitors [60-62].  
 
1.2.4.1 Vaccinia virus GLV-1h68 
Vaccinia virus GLV-1h68 is a large, complex enveloped virus that belongs to 
the poxvirus family. It is derived from the LIVP strain (Lister strain from the 
Institute for Research on Viral Preparations, Moscow) [63]. The linear, double-
stranded DNA genome has a size of about 190 kbp. The virus strain GLV-1h68 
was attenuated by inserting 3 expression cassettes into the genome encoding 
for marker proteins: i) the Renilla luciferase-Aequorea GFP (green fluorescent 
protein) fusion protein (ruc-GFP) into the F14.5L locus, ii) β-galactosidase 
(lacZ) into the thymidine kinase (tk) locus J2R, and iii) β-glucuronidase (gusA) 
into the A56R hemagglutinin locus (Figure 3).  
 
 
Figure 3. The three expression cassettes of GLV-1h68, which encode for marker proteins. 
Renilla luciferase-Aequorea GFP fusion protein (ruc-GFP) was inserted into the F14.5 locus. 
The β-galactosidase (lacZ) gene was inserted into the thymidine kinase (tk) locus J2R. The β-
glucuronidase (gusA) gene was inserted into the A56R hemagglutinin locus. Modified from 
Zhang et al., 2007. 
Thus, it contains an inactive thymidine kinase gene, shows reduced toxicity, and 
enhanced tumor-selective replication compared with its parental LIVP strain and 
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other strains, such as Western Reserve (WR). GLV-1h68 selectively infects 
tumor cells and has been proven to be non-toxic towards healthy cells. In nude 
mice GLV-1h68 caused regression and elimination of human breast tumor 
xenografts [63]. 
GLV-1h68 has been prepared and kindly provided by Genelux Corporation, San 
Diego, CA, USA. 
 
1.2.4 Vaccinia virus resistant tumor cell lines 
In spite of great achievements of oncolytic viruses for selectively killing cancer 
cells with moderate toxicity for healthy non-malignant tissues, virus-induced 
oncolysis is often limited by poor access of oncolytic viruses to tumor sites. 
Another limitation is caused by primary resistances against the available viro-
therapeutics, which are mainly used in monotherapy. Thus, trying to combine 
virotherapeutics with drugs, such as chemotherapeutics, epigenetically 
modulating agents or radiotherapy might be a solution to overcome these 
primary resistances.  
In preliminary work, the well characterized tumor cell panel of the National 
Cancer Institute in Bethesda, MD, USA (NCI-60 panel) was screened in vitro to 
identify cancer cell lines, which are primarily resistant towards the therapy with 
oncolytic vaccinia virus (unpublished data by Christian Raff, University Hospital 
Tübingen). Thus, three different cancer cell lines were chosen that have shown 
a high or partial resistance towards vaccinia virus: HCT-116 and HCT-15, which 
both are colon cancer cell lines and ACHN, a renal adenocarcinoma cell line. 
Additionally, a murine colon cancer cell line, Colon-26, was selected to test 
differences in resistance aspects compared to the above-mentioned three 
human cancer cell lines.  
Depending on the remnant tumor cell mass after treatment with vaccinia virus at 
96 hours post infection (hpi), high-grade resistance equals remaining tumor cell 
mass >75 %, partial resistance equals remaining tumor cell mass between 50-
75 % and cell lines displaying tumor cell mass below 50 % at 96 hpi were 
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classified as susceptible to virus-induced oncolysis (using a multiplicity of 
infection (MOI) of 0.1, respectively; i.e., one virus particle per addressed tumor 
cell).  
 
1.3 Epigenetics 
1.3.1 The structure of the genome 
 
Figure 4. Schematic organization from the DNA double helix to the entire chromosome 
[64]. 
Chromatin consists of DNA (deoxyribonucleic acid), histone and nonhistone 
proteins, located within the nucleus of eukaryotic cells (Figure 4). Besides the 
storage of the genetic information are the main functions to condense the DNA, 
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control gene activity, and other cellular processes, for example DNA replication 
and repair. Chromatin has two different conformation states: heterochromatin, a 
silent conformation, and consequently a densely packed transcriptionally inert 
structure and euchromatin, a decondensed and transcriptionally active 
conformation. The arrangement of the chromatin is among other things 
regulated by different histones H1 - H4. The nucleosome, a subunit of 
chromatin, consists of an octamer of core histones (two H2A-H2B dimers and 
two H3-H4 dimers). About 147 base pairs of DNA are folded around this histone 
octamer. The DNA between two nucleosomes is called linker DNA and has a 
length of about 10-80 base pairs. Histone H1 binds to the linker DNA between 
the nucleosomes [64-67]. The tails of the histone proteins are reachable on the 
nucleosome surface for posttranslational alterations, which lead to changes in 
conformation and therefore interfere with gene accessibility and thus gene 
activation or silencing [68]. 
 
1.3.2 Epigenetic mechanisms 
The term epigenotype or epigenetics was characterized by Conrad Waddington 
in 1942 [69]. The definition of epigenetics is “the study of the mechanism of 
temporal and spatial control of gene activity during the development of complex 
organisms” [70] or “the study of mitotically and/or meiotically heritable changes 
in gene function that cannot be explained by changes in DNA sequence” by 
Arthur Riggs [71]. 
The two main epigenetic changes are DNA methylation or demethylation and 
modifications of histones. Both have an impact on transcription and gene 
expression. Besides, histone modifications also induce long-term effects by 
defining heterochromatin conformation for the next cell generation [72, 73]. The 
combination of epigenetic modifications and genetic aberrations leads to 
alteration of gene expression and may result in the development of cancer. 
Quite often, genes with tumor suppressor activity are epigenetically silenced. 
[3]. 
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1.3.3 DNA methylation 
DNA methylation regulates the gene expression by adding a methyl group 
through DNA methyltransferases (DNMTs) at the 5’ carbon position of a 
cytosine ring. Some cytosine rings are at cytosine-guanosine dinucleotide 
(CpGs) sites, so called CpG islands, close to the promoter region. If these CpG 
islands are methylated, different transcription factors have less access to the 
binding sites resulting in transcriptional silencing. 
In human malignant cancer cells, abnormal DNA methylation patterns as well as 
increased expression of DNMTs were found. DNA promoter hypermethylation in 
tumor cells causes transcriptional silencing of different genes, e.g. tumor 
suppressor genes. Furthermore, hypomethylation in repetitive sequences leads 
to chromosomal alterations and genetic instability [74-77]. Different inhibitors of 
DNA methylation are under investigation for the treatment of various cancer 
entities. 
 
1.3.4 Histone modification 
Histone modifications are posttranslational epigenetic processes, which 
influence gene regulation without changing the DNA sequence [72]. Two 
important modifications are histone acetylation and histone methylation.  
Acetylation and deacetylation of histone tails are regulated by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). HATs transfer 
acetyl groups to the lysine residues at the amino-terminal tail of histones, thus 
transcription factors as polymerases have access to the DNA and the 
transcription rate is increased. HDACs, the antagonists of HATs, remove acetyl 
groups from lysine residues of histone proteins, the chromatin condenses and 
represses the transcription of genes, which is also called gene silencing [78]. 
Errors in the regulation of these processes, as for instance inactive HATs or 
overexpression of HDACs seem to provoke cancer formation [79-81]. Lower 
levels of histone acetylation were shown in solid tumors, whereas an 
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upregulation of HDACs was found in prostate cancer, gastric cancer and colon 
cancer [82-84].  
Hence, HDACs are target structures for tumor therapy. So far, 18 different 
HDACs were identified, which are subdivided into four classes (classes I - IV) 
depending on their homology to yeast histone deacetylases. Class I HDACs are 
homologous to the yeast RPD3 gene and mainly regulate cell proliferation and 
apoptosis. Class II HDACs are homologous to the Had1 gene and regulate 
amongst others cell migration and angiogenesis [85]. Class III HDACs have a 
homology to the Sir2 (silent information regulator 2) gene and regulate gene 
expression. Class IV HDACs combine features of class I and II [86].  
As mentioned before, another histone modification is histone methylation. It 
mainly occurs on histones H3 and H4. Contrary to histone acetylation, which 
correlates primary with transcriptional activation, histone methylation can 
indicate either activation or repression of transcription, depending on the 
methylation sites and on the number of methyl groups added [87, 88]. 
 
1.3.5 Histone deacetylase inhibitors 
Altered expression of HDACs and thus dysfunction of transcriptional processes 
is associated with different types of cancers. As described above, over-
expression of diverse HDACs seems to increase cancer formation, e.g. over-
expression of HDAC1 can lead to prostate and gastric cancer, overexpression 
of HDAC2 to colon cancer [82-84]. Hence, HDACs are promising targets for 
therapeutic interventions.  
HDAC inhibitors (HDACi) represent an interesting class of potent anticancer 
compounds with activity against an immense spectrum of neoplasms at 
concentrations that are well tolerated and minimally toxic for the host [89]. 
Because of different chemical structures, HDACi are a heterogeneous family, 
divided into 6 groups: short-chain fatty acids, hydroxamates, benzamides, cyclic 
tetrapeptides, electrophilic ketones and miscellaneous [90]. Some HDACi only 
inhibit specific HDACs, other pan-HDACi have an effect on multiple HDAC 
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groups [91]. Generally, the HDAC inhibition leads to a relaxed chromatin 
structure and thus to an increased transcriptional activity of former silenced 
genes (Figure 5). 
 
 
Figure 5. HDACi compounds such as SAHA can upregulate gene expression. A) HDACs 
bind to the histone proteins and suppress transcription. B) HDAC inhibitors, in this case SAHA, 
block HDAC enzymatic activity and thus induce increased transcriptional activity. Figure was 
modified from Kramer et al. [92]. 
HDACi are able to induce growth arrest and apoptosis in transformed cells by 
accumulation of acetylated histone proteins in nucleosomes [86, 93]. 
Additionally, HDACi might affect neoplastic growth and suppress angiogenesis 
by downregulation of the vascular endothelial growth factor (VEGF), basic fibro-
blast growth factor (bFGF) and hypoxia-inducible factor 1-alpha (HIF1-a) [94]. 
Furthermore, HDACi sensitize cells, especially tumor cells for other therapeutic 
agents. Compared to tumor cells, HDACi are well tolerated by non-transformed 
cells [95]. Nevertheless, the effect of HDACi is unspecific and results in a 
generally increased transcriptional rate of all genes. Different studies 
demonstrated that up to 20% of all known genes in transformed cells are 
affected by HDACi [96]. 
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Because of the impact on tumor cells, HDACi are interesting combination 
partners for new therapy options. Thus, trying to combine HDACi with drugs, for 
instance chemotherapeutics, or radiotherapy might be the key to overcome 
tumor resistance [97-99]. 
The chosen epigenetic compounds in this dissertation are different HDAC 
inhibitors. A broad number of HDACi has been isolated from natural sources, for 
example resveratrol and kaempferol. Others have been synthetically developed, 
such as SAHA (suberanilide hydroxamic acid) [90]. 
 
1.3.6 Resveratrol 
Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is a naturally occurring phytoalexin 
that belongs to the group of polyphenols. It is found in grapes, peanuts, red 
wine and other berries [100, 101]. 
 
Figure 6. Structural formula of resveratrol.  
Plants produce stilbenes as a defense reaction in response to stress like UV-
irradiation, bacterial or fungal infection [102]. One of the most discussed effects 
of resveratrol is the so called “French paradox”, which might explain the lower 
incidence of cardiovascular diseases by low to moderate wine intake, due to the 
antioxidant activity and the inhibition of platelet aggregation [103-105]. More-
over, anti-inflammatory [106], cardioprotective [107], and anti-proliferative 
effects as well as cancer chemopreventive activities were shown [108]. Further 
modulations were identified, for instance the inhibition of phosphodiesterases -
1, -3 and -4 [109], activation of protein kinases [110], inhibition of the protea-
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some by modulating the NF-kB (nuclear factor kappa-light-chain-enhancer of 
activated B-cells) pathway and the activation of sirtuin deacetylases [111]. 
These modulations extend the lifespan in yeast by up to 70% [112]. 
Since the oral bioavailability of resveratrol is considered to be less than 1%, it is 
hard to reach suitable levels of resveratrol through oral administration in vivo 
[113]. The development of effective prodrugs of resveratrol to reach higher 
concentrations in vivo remains to be explored [114].  
 
1.3.7 Kaempferol 
Kaempferol (3,5,7,4’-Tetrahydroxyflavone) is a natural polyphenol that belongs 
to the group of flavonoids [115]. 
 
 
Figure 7. Structural formula of kaempferol. 
Kaempferol mainly occurs in vegetables and fruits, predominantly in tomatoes, 
endive, hops, honey, strawberries and green tea [116-121]. As well as 
resveratrol, kaempferol also has anti-proliferative and anti-cancer activity 
resulting in apoptosis in different tumor entities, such as leukemia, prostate 
cancer, non-small cell lung cancer, oral cavity cancer and colon cancer [122-
126]. 
Plasma concentrations after oral consumption reach up to 0.1 µM, whereas 
plasma concentrations after intravenous injection reach 4-16 µM [127].  
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1.3.8 SAHA 
SAHA (suberanilide hydroxamic acid) also known as Vorinostat, marketed 
under the name Zolinza® by Merck, is the first HDACi approved by the US Food 
and Drug Administration (FDA) for the treatment of advanced cutaneous T cell 
lymphoma (Zolinza® (vorinostat) Capsules. Full Prescribing Information. Merck 
& Co., Inc., Whitehouse Station, NJ 08889, USA. Retrieved 1 September 2016). 
SAHA is a synthetic hydroxamic acid of hybrid polar compounds that induces 
growth arrest and apoptosis in transformed cells [128]. 
 
Figure 8. Structural formula of SAHA. 
Recent phase I and II trials have shown effects against recurrent glioblastoma 
multiforme [129], breast cancer [130], leukemia [131] and non-small-cell lung 
cancer [132]. A further effect is the clearance of latent infection of HIV [133, 
134]. 
Compared to resveratrol and kaempferol, SAHA shows a good oral bio-
availability [135]. SAHA selectively modifies the transcription of a few genes, 
whereby healthy cells are at least 10 times more resistant than transformed 
tumor cells to SAHA [136]. 
 
1.3.9 Advantages and disadvantages 
In contrast to synthetically produced SAHA, resveratrol and kaempferol are 
naturally occurring epigenetic modulating agents, which are present in fruits and 
vegetables and are therefore less toxic. Nevertheless, with these dietary agents 
it is hard to reach concentrations under physiological conditions that are high 
enough to achieve HDACi activity in vivo. Thus, these dietary compounds need 
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higher concentrations for inhibitory capability, compared to SAHA, which is 
effective even in a low micromolar range [137].  
Therefore, SAHA offers an advantage, also because it is applicable in the daily 
clinic routine and has its approval by the FDA for the treatment of cutaneous T 
cell lymphoma.  
 
1.4 Combination therapy of Vaccinia Virus GLV-1h68 and epigenetic 
modulating agents 
Combinatorial treatments of different viruses, such as reovirus, vaccinia and 
HSV with drugs or radiation have been performed so far and showed good 
response rates [138-141]. Further trials combining HDACi with VACV have 
been investigated. It is presumed that HDACi decline the response of cancer 
cells to interferon and hence enhance susceptibility to viral infection [43, 44]. 
Nevertheless, it is difficult to distinguish whether oncolytic viruses or the 
combinatorial treatment agent is contributing to these responses. This can be 
clarified in further investigations by randomized phase 3 trials [40]. 
 
1.5 Aim of this dissertation  
Besides the improvement of new therapy options for cancer, the prognosis for 
patients with advanced or relapsing colorectal or renal cancer remains poor.  
Oncolytic viruses have emerged as powerful anticancer therapeutics for 
selectively killing tumor cells with moderate toxicity for healthy non-malignant 
tissues. However, virus-induced oncolysis is often limited by poor access to 
tumor sites. Therefore, the administration of combinatorial treatments of onco-
lytic viruses with histone deacetylase inhibitors (HDACi) with the purpose to 
overcome both infection barriers and therapy resistance mechanisms, might be 
a first starting point [142]. 
The aim of this dissertation was to overcome current high-grade tumor cell 
resistance to virotherapy by combined application of vaccinia virus GLV-1h68 
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and distinct HDACi compounds, such as resveratrol, kaempferol or SAHA. A 
further goal was to determine whether these HDACi compounds can enhance 
the potency of VACV GLV-1h68 in infection-resistant cancer cell lines and 
which concentrations are needed to overcome these limitations. 
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2. Material and methods 
2.1 Cell culture 
2.1.1 Materials 
Cell culture Materials 
Laminar flow work bench HERAsafe®, Heraeus 
Incubator  HERAcell®, Heraeus 
Sonifier 450 Branson, Emerson Industrial 
Centrifuge Megafuge 2.0 R, Heraeus 
Microscope CK40, Olympus Corporation 
IX50, Olympus Corporation 
75 cm2 tissue culture flasks  
150 cm2 tissue culture flasks 
TPP, Techno Plastic Products AG 
Greiner Bio One  
24-well microplate 
96-well microplate 
TPP, Techno Plastic Products AG 
Costar, Corning Life Sciences 
Dulbecco’s modified Eagle medium 
(DMEM); with stable L-glutamine with 
4.5g/l glucose 
Sigma-Aldrich Corporation 
Dulbecco’s phosphate buffered saline 
(PBS); without Ca2+ and Mg2+ 
Sigma-Aldrich Corporation 
Fetal bovine serum (FBS) PAA Laboratories AG 
Ethylendiamintetraacetate-trypsin 
(EDTA-trypsin) 
PAA Laboratories AG 
Dimethylesulfoxide (DMSO) Sigma-Aldrich Corporation 
15 ml tubes 
50 ml tubes  
Greiner Bio One 
BD Biosciences  
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Cryovials Corning Life Sciences 
Isopropanol chamber “Mr. Frosty” Nalgene® labware 
Trypan Blue solution 0.4 % Sigma-Aldrich Corporation 
ddH2O Millipore BioPak Polisher, Merck 
Table 1. Cell culture materials 
DMEM, PBS, FBS and EDTA-trypsin were stored at 4° C, Trypan Blue solution 
and DMSO were stored at room temperature (RT) during time of use. EDTA-
trypsin and FBS were stored at -20° C before use, PBS at RT. FBS was heat-
inactivated for 30 minutes at 56° C before used. 
 
2.1.2 Cell lines 
Cell line Origin and histology Species Comment 
ACHN Renal cell carcinoma human Can Res 42; 4948-
4953, 1982 
HCT-15 Colon adenocarcinoma human Can Res 39; 1020-
1025, 1979 
HCT-116 Colon carcinoma 
 
human Can Res 41; 1761-
1756, 1981 
Colon-26 
CV-1 
Colon adenocarcinoma 
African green monkey 
kidney fibroblasts 
murine 
simian 
 
Table 2. Cell lines 
ACHN, HCT-15 and HCT-116 cells were chosen from the NCI-60 anti-cancer 
cell line panel from the U.S. National Cancer Institute and purchased from 
Charles River Laboratories. The murine cancer cell line Colon-26, purchased 
from Tumorzellbank, DKFZ Heidelberg, was selected to see if results differ to 
human cell lines and if it might be of use for further experiments in a mouse 
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model. CV-1 cells were purchased from Genelux Corporation, San Diego, CA, 
USA. 
 
2.1.3 General cell culture 
All cell lines were cultivated in DMEM with 10 % heat-inactivated fetal bovine 
serum (FBS) (DMEM-10) at 37° C in a humidified incubator in a 5 % CO2 
atmosphere. Cells were kept in 75 cm2 or 150 cm2 tissue culture flasks with 
vented caps as permanent cell cultures and were maintained as adherent 
monolayer. The media did not contain any antibiotics or fungicides. The cells 
were treated under a HERAsafe® laminar flow workbench under sterile 
conditions. The complete media and buffers needed for cell culture were pre-
warmed to 37° C. When cell cultures reached a confluent level, cells were 
passaged (two or three times a week) to avoid overgrowth and lack of nutrients. 
To harvest cells, spent cell culture medium was discarded and cells were 
washed once with pre-warmed PBS (37° C) to eliminate dead cells and remove 
left over medium, calcium and magnesium, which would inhibit the activity of the 
ETDA-trypsin. To detach the cell layer, cells were incubated with warmed 
EDTA-trypsin (0.05 %) at 37° C for a few minutes. When all cells were 
detached, fresh DMEM-10 was added to inactivate EDTA-trypsin. Cells were 
resuspended thoroughly, depending on the cell lines between one tenth and 
one twentieth of the cell solution was transferred into a new flask containing 
DMEM-10.  
 
2.1.4 Cryopreservation of cells 
Cell lines in continuous culture are inclined to genetic drift or microbial 
contamination. Therefore, cells were preserved for long-term storage and frozen 
at -180° C in cryovials. Cells were detached from the tissue culture flasks as 
described in 2.1.3. Cells were resuspended and centrifuged at 1200 revolutions 
per minute (rpm) for 5 minutes at RT. Supernatant was discarded and the cell 
pellet was resuspended in DMEM containing 10 % dimethylsulfoxide (DMSO) 
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and 20 % FBS. DMSO reduces the freezing point of the medium and allows a 
slower cooling rate, which preserves cells from damage and cell death [143]. 
Aliquots were dispensed into cryovials and were stored in an isopropanol 
chamber (Mr. Frosty, Nalgene labware) at -80° C overnight. On the next day, 
frozen cells were transferred to a -180° C freezer for long-term storage.  
 
2.1.5 Thawing of cells for recultivation 
To recultivate cells, the cryovials were thawed in a water bath at 37° C, diluted 
with pre-warmed DMEM-10, and centrifuged at 1200 rpm for 3 minutes at RT. 
Supernatant was discarded to remove toxic DMSO. Cell pellet was 
resuspended in 10 ml DMEM-10 and cells were transferred into a new 75 cm2 
tissue culture flask. 
 
2.1.6 Determination of cell number in solution 
Before seeding cells, their exact number had to be counted using an improved 
Neubauer hemocytometer. Cells were harvested as described in 2.1.3. Then, 
cells were resuspended in DMEM-10 and 10 µl of the cell suspension was 
added to 90 µl trypan blue (0.4 % w/v). Trypan blue is taken up only by dead 
cells, which appear dark blue under the microscope, whereas living cells have a 
white appearance. 10 µl of the suspension were pipetted between the chamber 
of the hemocytometer and the cover glass. Cells were counted in the central 
gridded four large squares under the inverted microscope. One square contains 
a defined volume of 0.1 µl. The average cell number of the four squares was 
multiplied with 10.000 resulting in the number of cells per ml. In case of dilution 
with trypan blue the result had to be multiplied with the dilution factor. 
 
2.2 Virological methods – Virus infection of cells 
Cells were seeded in 24-well plates at a density of 4 x 104 cells in 500 µl 
DMEM-10 per well and allowed to adhere over 48 h. After 48 h, cells were 
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infected with VACV GLV-1h68 at different multiplicities of infection (MOI) or 
mock-infected to determine the final MOI for further experiments. MOI describes 
the number of infectious virus particles per cancer cell at the time point of 
infection. The setting for the treatment is described in Figure 9.  
 
 
Figure 9. Setting for virotherapy. Application scheme for the determination of suitable MOIs 
for each cell line. Tumor cells were plated and infected after 48 h with GLV-1h68 or mock-
treated. One hour post infection (hpi) medium change was performed. 72 hpi, remnant cell 
masses were quantified by SRB cytotoxicity assay.  
VACV GLV-1h68 was thawed carefully and sonicated for 30 seconds at 4° C in 
order to disaggregate virus particles. Depending on the needed MOI, the virus 
was diluted in room-tempered DMEM supplemented with 2 % FBS (DMEM-2). 
In the first step, medium was removed, and cells were gently washed once with 
pre-warmed PBS. Infection took place in 250 µl DMEM-2. Virus at different 
MOIs (0.0001, 0.001. 0.01, 0.1 and 1) was added to the 24-well plate in quadru-
plicates as described in Figure 10. Four wells were mock-infected, therefore 
250 µl DMEM-2 without virus was added to these wells. After infection, the 24-
well plates were placed in the incubator at 37° C to allow the virus to adhere to 
the cells. Every 20 minutes, the plates were gently swayed to ensure an equal 
virus infection throughout the cell layer. One hour post infection (hpi), the 
inoculum was removed and 1 ml fresh DMEM-10 was added to each well. At 72 
hpi tumor cell viability was analyzed by the sulforhodamine B (SRB) assay (as 
described in 2.5.1). 
VACV GLV-1h68 has been prepared and kindly provided by the Genelux 
Corporation, San Diego, CA, USA. 
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Figure 10. Pipetting scheme for treatment with different VACV GLV-1h68 concentrations. 
Cells were infected at different MOIs or mock-infected in quadruplicates. Same color indicates 
same virus concentration. Four wells were mock-treated with DMEM-2 solely (black wells).  
 
2.3 Epigenetic methods – Treatment with the HDAC inhibitors 
Cells were treated with different epigenetically modulating agents such as 
resveratrol, kaempferol and SAHA. The tumor cell lines were treated 24 h after 
seeding, as shown in the setting (Figure 11).  
 
 
Figure 11. General application scheme for treatment with HDACi. Tumor cells were plated 
and treated with epigenetic compounds 24 h after seeding. 96 h later, remnant cell masses 
were quantified by SRB viability assay. 
Cells were seeded in 24-well plates at a density of 4 x 104 cells in 500 µl 
DMEM-10 per well and allowed to adhere over 24 h. After 24 h, the epigenetic 
compound was thawed in the water bath at 37° C. Depending on the needed 
dilution, resveratrol, kaempferol or SAHA was diluted in pre-warmed DMEM-10. 
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Medium was removed, and cells were treated in triplicates with 500 µl of the 
epigenetic compound at different concentrations, as shown in Table 3. 
Additionally, three wells were treated with 500 µl DMEM-10 solely (control). 
Thereafter, the 24-well plates were placed in the incubator at 37° C. 96 h later, 
SRB assay was performed. 
HDACi Concentrations 
Resveratrol 1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 50 µM, 100 µM 
Kaempferol 1 µM, 5 µM, 10 µM, 20 µM, 50 µM, 100 µM 
SAHA 0.5 µM, 1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 50 µM 
Table 3. Concentrations of the epigenetic compounds resveratrol, kaempferol and SAHA 
that were used in the experiments.  
 
2.4 Combinatorial treatment 
Cells were seeded in 24-well plates at a density of 4 x 104 cells in 500 µl 
DMEM-10 per well. After 24 h, supernatant was discarded, and cells were 
treated with 500 µl of different epigenetic compounds (resveratrol, kaempferol 
or SAHA). 24 h after treatment, the supernatant containing the epigenetic 
compound was transferred from each well to the corresponding well of an 
empty plate and was stored in the incubator. Cells were gently washed with 
PBS. VACV GLV-1h68 was thawed carefully and sonicated at 4° C for 30 
seconds. Depending on the needed MOI, the virus was diluted in room-
tempered DMEM-2. Infection took place in 250 µl DMEM-2. Virus was added to 
the 24-well plate in quadruplicates. Four wells were mock-infected with 250 µl 
DMEM-2 solely. The application scheme is shown in Figure 12. After infection, 
the 24-well plates were placed in the incubator for one hour at 37° C. Every 20 
minutes, the plates were gently swayed. 1 hpi, the inoculum was removed and 
replaced by the former medium containing the epigenetics, which had been set 
aside. 72 hpi different assays were performed as described in the following 
chapters. 
 
 
27 
 
Figure 12. Application scheme for the combinatorial treatment of VACV GLV-1h68 with 
HDACi. Tumor cells were plated. After 24 h, cells were treated with epigenetic compounds. 24 h 
later, cells were infected with GLV-1h68 or mock-infected. 72 hpi, remnant tumor cell masses 
were quantified by different assays, such as SRB cytotoxicity assay. 
 
2.5 Cell viability assays 
2.5.1 Suforhodamine B assay (SRB) 
Materials 
Tecan GENios Microplate Elisa 
Reader 
MTX lab system, Tecan group Ltd. 
Trichloroacetic acid (TCA) Carl Roth GmbH 
Sulforhodamine B Sigma-Aldrich Corporation 
Acetic acid (1 %) Merck 
Tris-base solution (10mM) Sigma-Aldrich Corporation 
Table 4. Materials for SRB assay 
To quantify the remaining tumor cell mass after treatment with epigenetically 
modulating agents and/or VACV GLV-1h68 infection, the sulforhodamine B 
assay (SRB) was performed [144]. SRB is the standard assay of the US 
National Cancer Institute (NCI) to measure the drug-induced cytotoxicity in cell 
cultures. The protein-binding dye sulforhodamine B binds to basic amino acid 
residues in TCA-fixed cells. The remaining cell mass of the differently treated 
cells can be quantified by the calculated amount of dye and thus by the 
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measured optical density (OD). The fewer cells remain, the more effective the 
virus is killing cells.  
Cells were treated and/or infected as described in 2.2, 2.3 and 2.4. After 120h, 
growth inhibition was evaluated by the SRB assay. First, supernatant was 
discarded, followed by fixation with 250 µl cold TCA solution (trichloroacetic 
acid, 10 % w/v, 4° C, 10 g in 100 ml distilled H2O) per well for 30 minutes at 4° 
C. After incubation, the TCA solution was discarded, and plates were gently 
rinsed with tap water for four times. Then, cells were dried overnight in a 
heating cabinet at 40° C. At this point plates can be stored indefinitely. In the 
next step, cells were dyed with the SRB staining solution (0.4 % w/v in 1 % 
acetic acid) for 10 minutes. The dye was removed, and cells were washed with 
acetic acid (1 % v/v) until all soluble red dye was removed. Plates were dried for 
at least 3 - 6 h at 40° C and measured within the following 48 hours. Before-
hand, photographs of the 24-well plates were taken (Figure 13) for further 
assays (2.8 Area calculation). 
 
Figure 13. Photograph of a 24-well plate containing ACHN cells after treatment with 
SAHA and infection with GLV-1h68. The 24-well plate was dyed with sulforhodamin B 
staining solution and dried overnight. Then, photographs were taken. 
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Bound dye was solubilized in 1 ml 10 mM Tris base (pH 10.5, 1.211 g in 1000 
ml ddH2O) per well for 10 minutes on a gyratory shaker. 80 µl of the colored 
solution was transferred to a transparent flat-bottom 96-well plate in duplicates 
for each sample. The optical density was measured in the Microplate Elisa 
Reader at 550 nm wavelength using the xFluor 4 software. The values should 
not exceed 1.8 OD units. If higher values were reached, samples were equally 
diluted with additional 500 µl Tris. 
Results were calculated using GraphPad Prism Software version 6.0 
(GraphPad Software, La Jolla, CA, USA). Mean of the duplicates was used for 
further calculation. Error bars were shown +/- SD. 
 
2.5.2 Resazurin-based viability assay 
Also called CellTiter-Blue assay. 
Materials 
Tecan GENios Microplate Elisa 
Reader 
MTX lab system, Tecan group Ltd. 
CellTiter-Blue© Kit Promega Corporations 
Table 5. Materials for the resazurin-based viability assay 
Resazurin-based viability assay is a cell viability assay that monitors cytotoxicity 
or proliferation of cells. Viable cells are able to reduce a particular dark blue 
non-fluorescent substrate, called resazurin to the pink product resorufin, which 
is extremely fluorescent. Resorufin diffuses out of the cell into the medium and 
thus a color change is visible. Dead cells are not able to reduce resazurin 
because of the loss of metabolic capacity, therefore no fluorescent signal is 
measureable at 595 nm wavelength. The increase of the fluorescence is 
proportional to the amount of viable cells. DMEM-10 is used as a negative 
control to detect background fluorescence. The CellTiter-Blue© Reagent is 
nontoxic, which allows further assays after measurement.  
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Cells were seeded at a density of 4 x 104 cells per well and treated and infected 
as described in 2.4. 120 h after seeding, cell viability was evaluated by 
CellTiter-Blue Assay© according to the manufacturer’s protocol [145, 146]. 
First, 600 µl supernatant from each well was gently removed so that 400 µl 
medium was left. 80 µl CellTiter-Blue© Reagent was added to each well in the 
assay plate and incubated at 37° C for 1 hour. To calculate the percentage of 
resorufin release, mock-infected wells were used as a 100 % control. Wells 
containing 400 µl DMEM-10 solely with 80 µl CellTiter-Blue© Reagent were 
used for background measurement. 100 µl of the colored solution was 
transferred to a transparent flat-bottom 96-well plate in duplicates for each 
sample including background measurement and mock control. Measurement 
was performed in the Microplate Elisa Reader at 595 nm wavelength using 
xFluor 4 software. In the end, values were compared to the background 
measurement (blank wells) and to the corresponding mock-treated wells. Mean 
of the duplicates was used for calculation using GraphPad Prism Software 
version 6.0 and was given in percent (GraphPad Software, La Jolla, CA, USA). 
Error bars were shown +/- SD. 
 
2.5.3 MTT assay 
Materials 
Synergy HT microplate reader BioTek Instruments GmbH 
MTT staining solution Sigma-Aldrich Corporation 
Hydrogen chloride (HCl) Merck 
Isopropanol Merck 
Table 6. Materials for MTT assay 
MTT is a rapid colorimetric assay, which is applicable as another cytotoxicity 
assay. It is based on the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) that is reduced to formazan when incubated with 
living cells. The yellow tetrazole MTT is reduced to purple-blue formazan, which 
 
 
31 
can be quantified by measuring at 570 nm and 650 nm wavelength in a 
spectrophotometer [147].  
Cells were seeded and treated as described before (2.4). Medium was 
discarded, and cells wells were gently washed with 500 µl PBS. Then, 250 µl 
MTT staining solution (2.5 mg/ml in DMEM without phenol red) was added to 
each well and incubated for 2 h at 37° C. After incubation, the staining solution 
was removed, and the bound dye was resolved in 1 ml MTT solvent (1 ml 10 % 
HCl in isopropanol) on a gyratory shaker until completely solubilized. 200 µl of 
the colored solution was transferred from each well to a transparent flat-bottom 
96-well plate in duplicates for each sample. Additionally, the background was 
determined by using the MTT solvent solely. Measurement took place in the 
Synergy HT microplate reader at 570 nm and 650 nm wavelength using the 
Gen5 software. 
The values were compared to the background measurement and to the 
corresponding mock-treated wells. The mean of the duplicates was used for 
further calculation using GraphPad Prism Software version 6.0. Mean values 
were shown +/- SD and given in percent. 
 
2.6 Cytotoxicity assay  
2.6.1 Lactate Dehydrogenase Assay (LDH assay) 
Materials 
Tecan GENios Microplate Elisa 
Reader 
MTX lab system, Tecan group Ltd. 
LDH-P mono (stored at 4° C) Analyticon Biotechnologies AG  
Triton X-100 Carl Roth GmbH 
Table 7. Materials used for Lactate Dehydrogenase Assay 
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LDH is an enzyme, which is used to evaluate damage and toxicity of cells and 
tissues. If cells are damaged and lose their membrane integrity, LDH present in 
the cytosol is released in the surrounding medium. The LDH release can be 
detected by the LDH-P mono Kit from Analyticon Biotechnologies AG. 
The released LDH in damaged cells catalyses the interconversion of lactate and 
pyruvate under simultaneous production of NAD+ into NADH in the culture 
medium. The LDH release is proportional to the amount of the NADH decrease, 
which can be measured at 340 nm extinction [148]. 
 
 
Cells were seeded and treated as described before (2.4). Additionally, another 
four wells were seeded, which were treated with Triton X-100 to obtain 100 % 
cell lysis (Triton control). After 120 h, the LDH solution was prepared according 
to the manufacturer’s protocol. Then, the Microplate Elisa Reader was prepared 
since the measurement should start immediately after adding the substrate. The 
mock control shows the basal cell death background. To obtain total LDH 
release 500 µl PBS/0.1 % Triton X-100 was added to the Triton X-100 control 
and incubated for 10 min at RT until all cells were lysed. 10 µl of supernatant 
(including the mock and Triton X-100 control) was transferred to a flat-bottom 
96-well plate in duplicates for each sample, after that 200 µl of the reaction 
solution was added. The well plate was measured at 340 nm wavelength using 
the Magellan software. The U/I values determined by the Elisa reader were 
used for the evaluation. The LDH release was calculated, and the mock-treated 
quadruplicates were set to 100 % LDH release control. The results were 
calculated using GraphPad Prism Software version 6.0 (GraphPad Software, La 
Jolla, CA, USA). Mean of the duplicates was used for further calculation. Error 
bars were shown +/- SD. 
 
LDH 
Lactate + NAD+ Pyruvate + NADH + H+ 
 
 
33 
2.7 Detection of GFP via fluorescence microscopy 
The cells in the 24-well plates were continuously examined under the 
microscope CK40 from Olympus. Cells were treated and infected as described 
in 2.2 and 2.4. At 24, 48 and 72 hpi, fluorescence microscopy was performed 
using the Olympus IX50 microscope including the Olympus U-RFL-T function to 
visualize the GFP expression. Phase contrast photographs were taken using 
the PhL ocular at 4x lens magnification. Additionally, fluorescence photographs 
were taken with the fluorescence light filter from the same spot as the phase 
contrast photographs. Pictures were taken with F-View Soft Imaging System 
and analySIS Software. Finally, phase contrast and fluorescence photos were 
overlaid using Adobe Photoshop 7. 
 
2.8 Area calculation 
Additionally, the cell-free area of the wells was identified to evaluate the 
differences that are clearly visible in the 24-well plates after coloring with SRB 
dye. Therefore, photographs of the SRB-colored plates (2.5.1, Figure 13) were 
taken with a Nikon D3000 Camera. The cell-free area was defined and 
calculated using Paint.NET and Image J respectively. 
First, the photographs were processed with Paint.NET (version 4.0.3). A single 
rectangle was adjusted to cover as much area of the well as possible without 
overcasting any outside part. For optimal comparison, the same rectangle size 
was used for every single well of the 24-well plate. 
A tonal separation value 2 was chosen, so that each pixel of the photograph 
was automatically assigned either to the value black or white, depending on its 
original color shade. The black area shows the cell layer, whereas the white 
area shows the cell-free area. The photographs were saved in the 32-bit png 
format. In the next step, the 32-bit png pictures were analyzed with Image J 
software (version 1.49). Area calculation was performed through histogram 
values. All values at 255, which represent the white pixels of the photographs, 
were divided by the complete count of pixels. 
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 𝑝𝑖𝑥𝑒𝑙	𝑤𝑖𝑡ℎ	𝑐𝑜𝑙𝑜𝑟	𝑣𝑎𝑙𝑢𝑒	255𝑡𝑜𝑡𝑎𝑙	𝑝𝑖𝑥𝑒𝑙	𝑐𝑜𝑢𝑛𝑡 	× 	100	 = 𝑎𝑟𝑒𝑎	𝑤𝑖𝑡ℎ	𝑤ℎ𝑖𝑡𝑒	𝑐𝑜𝑙𝑜𝑟	𝑣𝑎𝑙𝑢𝑒	[%] 
 
 
2.9 Virus growth curves 
Materials 
Reaction tubes 1.5 ml, 2 ml Eppendorf 
CV-1 cell line Genelux Corporation, San Diego, USA 
Carboxymethylcellulose sodium salt 
(CMC) 
Sigma Aldrich 
Crystal violet Fluka Chemie AG 
Table 8. Materials for virus growth curves 
Furthermore, virus growth curves were performed to determine the impact of 
the epigenetic compounds resveratrol or SAHA on the replication behavior of 
VACV GLV-1h68. 
Preparation  
Cells were seeded and treated with virus solely or combinatorial treatment with 
the epigenetic compound was performed. 24 h after seeding, cells were treated 
with resveratrol or SAHA. 24 h later, cells were infected with GLV-1h68 as 
described in 2.4. After infection with GLV-1h68, the rest of the inoculum was 
directly frozen at -80° C. 1 hpi, the supernatant was removed and replaced by 
the former medium containing the epigenetic compound, which had been set 
aside. 1 hpi, 24 hpi, 48 hpi, 72 hpi and 96 hpi cells were scraped off in medium 
with a sterile cell scraper. The quadruplicates, which were treated the same 
way, were transferred to one reaction tube. Samples were immediately frozen at 
-80° C.  
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Determination of the virus titer 
Samples were used to quantify virus replication by titration on CV-1 cells. CV-1 
cells were seeded into 24-well plates at a density of 1 x 105 per well. On the 
next day, when cells were confluent, frozen samples were thawed. Next, 
samples were vortexed and sonicated for 30 seconds. Dilution series at 10 folds 
from 10-1 to 10-6 were prepared using 100 µl from the sample and 900 µl 
DMEM-2. Medium was removed from CV-1 wells and 250 µl of each prepared 
dilution was transferred to the wells in duplicates. Afterwards, plates were 
placed in the incubator. Every 20 minutes, plates were gently swayed to ensure 
an equal virus infection throughout the cell layer. After one hour, 1 ml medium 
containing 1.5 % carboxymethylcellulose (CMC) sodium salt and 5 % FCS was 
added, and plates were placed in the incubator for 48 hours at 37° C. To 
visualize plaques, 250 µl crystal violet staining solution (11.1 % formaldehyde, 5 
% ethanol, 0.13 % crystal violet) was added to each well and plates were 
incubated at RT. After 4 h, supernatant including crystal violet was discarded 
and wells were washed with H2O until washing solution was clear. Next, the 24-
well plates were dried. 
To calculate virus titers in each well, unstained plaques were counted and titers 
were calculated as described below:  
𝑣𝑖𝑟𝑎𝑙	𝑡𝑖𝑡𝑒𝑟 = 	𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑝𝑙𝑎𝑞𝑢𝑒𝑠	 × 	𝑖𝑛𝑣𝑒𝑟𝑠𝑒	𝑜𝑓	𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑣𝑜𝑙𝑢𝑚𝑒	𝑜𝑓	𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛	𝑚𝑒𝑑𝑖𝑢𝑚	(0.25	𝑚𝑙)  
Plaques were counted only in those wells, which contained between 20 and 100 
plaques. Less than 20 plaques are imprecise, above 100 plaques calculation 
will be imprecise as well since plaques conflate. Results were shown in PFU/ml. 
Calculation was performed using GraphPad Prism Software version 6.0. Error 
bars were shown +/- SD. 
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2.10 Real-time Cellular Impedance measurement  
Materials 
xCELLigence Roche Applied Sciences 
E-Plate 96-well microplate Roche Applied Sciences, Indianapolis, 
IN, USA 
Triton X-100 Carl Roth GmbH 
Table 9. Materials used for xCELLigence 
The xCELLigence system allows real-time monitoring of cellular impedance. It 
performs non-invasive continuous monitoring of cell proliferation and viability via 
electrical impedance readout using interdigitated micro-electrodes located on 
the bottom of each well of the E-Plate 96 [149]. Cell attachment, spreading, and 
proliferation were monitored every 30 minutes for 120 h. After every step, the E-
Plate 96 was placed back immediately into the SP station in the incubator. 
Cells were seeded and treated as described above (2.4). 50 µl DMEM-10 was 
added to each well of the E-Plate 96 and background was measured in the SP 
instrument.  
Cell lines HDACi Concentration 
ACHN Resveratrol 2.5 µM 
5 µM 
SAHA 1 µM 
2.5 µM 
HCT-116 Resveratrol 10 µM 
20 µM 
SAHA 0.5 µM 
1 µM 
Table 10. HDACi concentrations used for xCELLigence 
 
 
37 
Cells (ACHN or HCT-116) were added to each well at a density of 2 x 103 cells 
per well in 100 µl DMEM containing 2.5 % FBS. The plate was placed back into 
the SP instrument, cell monitoring was started, and cell index was continuously 
monitored for 24 h. After 24 h, 10µl of the HDACi (SAHA or resveratrol) 
dissolved in DMEM containing 5 % FBS was added in triplicate samples at 
different concentrations as described in Table 10. 20 µl Triton X-100 was also 
added to specific wells as Triton X-100 control. Afterwards, the plate was placed 
back in the SP instrument. 
After 23 h, cells were infected with GLV-1h68 at MOI 0.01 in triplicate samples 
in a volume of 10 µl. As a control, a few wells were mock-infected by adding 10 
µl DMEM solely. After one hour, 40 µl DMEM containing 32.5 % FBS was 
added to each well to inactivate the free virus in the medium. Cell monitoring 
was stopped after 120 h. The measured impedance from each individual well 
was converted into cell index values (CI) by the RTCA Software (version 
1.2.1.1002, Roche Applied Sciences). 
2.11 Flow cytometric (FACS) analysis 
Materials 
Flow cytometer 
10 mg/ml RNAse, #EN0531 
75 % ethanol (stored at -20 ° C) 
Propidium iodide 
BD LSRII, BD Biosciences 
Fermentas, Life Sciences 
Merck 
Sigma-Aldrich Corporation 
Table 11. Materials for FACS 
Fluorescence activated cell sorting (FACS assay) analyzes cells according to 
their size, granularity or fluorescent characteristics by using flow cytometry. 
Different cell parameters can be distinguished by different fluorescence at the 
same time.  
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Flow cytometric analysis of cells stained with propidium iodide (PI) was used to 
detect the percentage of apoptotic cells. PI is solved in a hypotonic buffer, 
which is capable to dissolve the cell membranes. Thus, PI is able to reach the 
cell nucleus, and intercalates into double-stranded nucleic acids. Once PI is 
bound to the nucleic acids, its fluorescence can be measured. The reduced 
DNA content of apoptotic nuclei results in an unequivocal hypodiploid DNA 
peak. The peak can be quantified in the red fluorescence channels using a 
FACScan flow cytometer BD LSRII with an extinction of 490 nm and emission of 
635 nm. The PI staining is able to detect G0/G1-, S, and G2/M-phase cells as 
well as sub G1 cells (apoptosis) [150]. 
Preparation of the cells for the staining 
Cells were seeded and treated as described in 2.4. After 120 h, supernatant 
from 2 wells of the quadruplicates was transferred to a 15 ml Falcon-Tube. 
Subsequently, cells were washed with cold PBS, which was also collected. The 
remaining cell layer was treated with 200 µl trypsin per well until cells were 
completely detached. Cells were resuspended in 1 ml DMEM-10 and trans-
ferred to the tube. After centrifugation for 5 minutes at 1200 rpm, 4° C, cells 
were fixed with 1 ml ice-cold 75 % ethanol. Cells can be stored at 4° C for 
several days when fixed in ethanol.  
Cell staining 
Approximately 2 ml of cold PBS was added to the fixed cells. The samples were 
mixed and were centrifuged at 4° C for 10 minutes at 1500 rpm. Supernatant 
was discarded, and cell pellet was again resuspended in 1 ml cold PBS, 
centrifuged and PBS was discarded. Then, cells were stained with 200 µl 
propidium iodide/RNAse solution (50 µg/ml PI + 10 µg/ml RNAse in PBS) per 
tube and incubated for at least 20 min at 4° C in the dark. Cells were analyzed 
within 24 h using the flow cytometer BD LSRII and the FACS Diva Software.  
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2.12 Software 
Software 
Adobe Photoshop 7 Adobe Systems 
ChemSketch Version 14.0 ACD/Labs 
FACSDiva  BD Biosciences 
Gen5 Data analysis 1.11  
Graph Pad Prism 6.0 
BioTek Instruments GmbH 
GraphPad Software, La Jolla, CA, 
USA 
Image analysis  Olympus Corporation 
Image J (version 1.49) Wayne Rasband (NIH) 
Magellan Data analysis  Tecan group Ltd. 
Microsoft Excel for Mac 2011 Microsoft Corporation 
Microsoft Word for Mac 2011 Microsoft Corporation 
PaintNET (version 4.0.3) dotPDN LLC 
PTCA  Version 1.2.1.1002, Roche Applied 
Science 
xFluor 4 Tecan group Ltd. 
Table 12. Software used for the different methods  
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3. Results 
In order to establish an optimized application scheme for the combinatorial 
treatment of VACV GLV-1h68 and epigenetic compounds, in a first step the 
different agents were applied in monotherapy to determine suitable 
concentrations. The subsequent part of this chapter moves on with the 
combinatorial treatment. 
 
3.1 Identification of optimized concentrations of VACV GLV-1h68 for 
colorectal and renal adenocarcinoma cell lines 
For each tested cell line first a multiplicity of infection (MOI) was determined that 
was suitable for further experiments.  
To this end, all cell lines were infected with VACV GLV-1h68 using ascending 
viral concentrations: MOI 0.0001, 0.001, 0.01, 0.1 and 1. Four wells were mock-
infected. At 72 hpi, the remaining tumor cell mass was determined, using the 
SRB cytotoxicity assay. Furthermore, to confirm the efficacy of infection and 
replication of GLV-1h68 in colorectal cancer and renal adenocarcinoma cell 
lines, the virus-mediated expression of the Renilla Luciferase green fluorescent 
fusion protein (RUC-GFP) was monitored by fluorescence microscopy (Figure 
15). 
 
3.1.1 SRB assay 
The 75 % line was charted in the diagrams as the threshold between high-
grade resistant and partially resistant tumor cell lines. If remnant tumor cell 
mass was >75 % after treatment with vaccinia virus at MOI 0.1 and 96 hpi, the 
cell line was classified as high-grade resistant. Partial resistance is defined as 
remaining tumor cell masses between 50 - 75 %, and tumor cell masses below 
50 % at 96 hpi are classified as tumor cell lines that are susceptible for virus-
induced oncolysis (Christian Raff, work in progress).  
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Since the aim of this study was to investigate whether a combinatorial treatment 
of VACV GLV-1h68 and epigenetic compounds was superior to the respective 
mono-treatments, a MOI, which resulted in a remaining tumor cell mass above 
or around 75 % was chosen for each cell line. The threshold of 75 % was also 
used for the epigenetic compounds. Furthermore, in this study a different 
application time was chosen for the epigenetic compounds, compared to 
infection with GLV-1h68, since both application times were combined in co-
treatment setting (compare 3.6). 
 
 
Figure 14. Determination of a suitable MOI of VACV GLV-1h68 for each cell line. 48 h after 
seeding, cells were mock-treated or infected with VACV GLV-1h68 at different multiplicities of 
infection (MOI). At 72 hpi, SRB viability assay was performed to quantify remnant tumor cell 
mass. Error bars indicate +/- SD. Mean of three independent experiments performed in quadru-
plicates is shown. The mock-treated quadruplicate was set to 100 % cell mass. The green-
colored bars show the MOIs, which were chosen for further experiments. As described above, 
the 75 % line was charted as the threshold between high-grade resistant and partially resistant 
tumor cell lines. 
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As seen in Figure 14, the oncolytic effect of VACV GLV-1h68 increased with 
ascending MOIs in all tumor cell lines. Viral infection with low MOIs showed only 
a marginal reduction of cell masses compared to the mock-treated controls. The 
three cell lines ACHN, HCT-116, and Colon-26 were susceptible to viral 
cytotoxicity with more than 80 % of cells being lysed at 72 hpi at MOI 1. By 
contrast, cell line HCT-15 was less susceptible with a remaining cell mass of 60 
% at MOI 1. 
 
3.1.2 Fluorescence monitoring 
 
 
 
 
 
 
43 
 
 
 
Figure 15. Fluorescence monitoring of VACV GLV-1h68. 48 h after seeding, tumor cells 
were infected with different concentrations of VACV GLV-1h68 or mock-treated. Fluorescence 
microscopy photos were taken 24, 48 and 72 hpi. One representative out of three independent 
experiments performed in quadruplicates is shown. Mock-treated cells did not show any green 
fluorescence. By contrast, depending on the MOI, virus-infected cells showed an increasing 
fluorescence intensity. 
GLV-1h68 replicated in all four cell lines, but the replication efficacy between 
the infected cell lines varied (Figure 15). At 24 hpi, only in HCT-116 cells a 
slight fluorescence signal was visible at MOI 1. In contrast, at 48 hpi at MOI 1 
and 0.1, cells emitted higher fluorescence intensities in each cell line. At 72 hpi, 
the infection at MOI 1 and MOI 0.1 exhibited the strongest GFP expression and 
the cell layer was already visibly reduced in each cell line. Taken together, in 
both experiments the efficacy of infection and replication was superior in HCT-
116 cells compared to the other cell lines. 
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For further combinatorial treatment, those MOIs were chosen that might 
enhance cell death with the different epigenetic compounds. Accordingly, for 
both ACHN and HCT-116 cells, MOI 0.01 was selected since MOI 1 and 0.1 
reduced cell mass already too much (Figure 14). By contrast, MOI 0.1 was 
selected for HCT-15 and Colon-26 cells. 
 
3.2 Identification of optimized concentrations of resveratrol for the 
epigenetic treatment of colorectal and renal adenocarcinoma cell 
lines 
 
Figure 16. Cytotoxic effect of resveratrol (RV) on colorectal and renal adenocarcinoma 
cell lines. 24 h after seeding, the cell lines were treated with resveratrol at different 
concentrations or remained untreated (control). 96 h after treatment, SRB viability assay was 
performed. Error bars indicate +/- SD. Mean of three independent experiments performed in 
triplicates is shown. The mock-treated triplicate was set to 100 % cell mass. The green bars 
indicate the concentrations that were selected for combinatorial treatment. 
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Initially, cells were treated with different concentrations of resveratrol to 
evaluate overall HDAC inhibition in a concentration range from 1 µM until 100 
µM. 96 h after treatment, SRB assay was performed to evaluate cytotoxic 
effects.  
Most of the cell lines responded only slightly to low resveratrol concentrations 
and thus only showed small differences to the control. In contrast, ACHN cells 
showed a reduction of cell mass in the range of 13 – 37 % at 2.5 and 5 µM 
resveratrol, respectively. While ACHN cells were almost completely eradicated 
at a concentration of 10 µM, this effect took place at 50 µM for HCT-15 and 
Colon-26 cells, and at 100 µM for HCT-116 cells (Figure 16). Therefore, 
resveratrol concentrations of 10 and 20 µM were chosen for all cell lines except 
for ACHN. For ACHN, concentrations of 2.5 and 5 µM were chosen.  
 
3.3 Identification of optimized concentrations of kaempferol for the 
epigenetic treatment of colorectal and renal adenocarcinoma cell 
lines 
All cell lines were treated with different concentrations of kaempferol to evaluate 
overall HDAC inhibition in a concentration range from 1 µM until 100 µM. 96 h 
after treatment, SRB assay was performed to evaluate cytotoxic effects. 
Since kaempferol showed less cytotoxic effects compared to the monotherapy 
with resveratrol or SAHA (see 3.2 and 3.4), concentrations of 10 µM and 20 µM 
were selected for each cell line for further combinatorial experiments. 
Concentrations around 10 µM and 20 µM were between the 75 % threshold and 
100 % (Figure 17). Low kaempferol concentrations did not show a reduction of 
cell mass compared to the control, whereas higher concentrations, e.g. 50 µM 
reduced cell mass in ACHN, HCT-15, and Colon-26 by more than 60 %. In 
HCT-116 cells, at a concentration of 50 µM resveratrol, 62 % cell mass was left 
96 h after treatment.  
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Figure 17. Cytotoxic effect of kaempferol (KMF) on colorectal and renal adenocarcinoma 
cell lines. 24 h after seeding, cells were treated with kaempferol at different concentrations. 4 
wells remained untreated (control). 96 h later, cell mass was quantified via SRB viability assay. 
Error bars indicate +/- SD. Mean of three independent experiments performed in triplicates is 
shown. The mock-treated triplicate was set to 100 % cell mass. The green bars indicate the 
concentrations, which were selected for combination therapy with VACV GLV-1h68. 
 
3.4 Identification of optimized concentrations of SAHA for the 
epigenetic treatment of colorectal and renal adenocarcinoma cell 
lines 
All cell lines were treated with different concentrations of the potent epigenetic 
compound SAHA to evaluate overall HDAC inhibition in a concentration range 
from 1 µM until 50 µM. 96 h after treatment, SRB assay was performed to 
evaluate cytotoxic effects. 
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Figure 18. Cytotoxic effect of SAHA on colorectal and renal adenocarcinoma cell lines. 
Cells were treated with rising SAHA concentrations 24 h after seeding or remained untreated 
(control). 96 h later, cell mass was quantified via SRB assay. Error bars indicate +/- SD. Mean 
of three independent experiments performed in triplicates is shown. The mock-treated triplicate 
was set to 100 % cell mass. The green bars indicate the concentrations, which were selected 
for combinatorial treatment with VACV GLV-1h68. 
Figure 18 illustrates the cytotoxic effect of rising concentrations of SAHA in 
different tumor cell lines. 96 h after treatment, except for HCT-15, remarkable 
inhibition values for 5 µM were detected in each cell line, with a reduction of cell 
mass in the range of 72 - 88 %, depending on the cell line. In HCT-15 cells, 5 
µM reduced cell mass to 59 %. Consequently, low concentrations were selected 
for combinatorial treatment: concentrations of 1 µM and 2.5 µM were chosen for 
ACHN, HCT-15 and Colon-26, whereas for HCT-116, lower concentrations of 
0.5 µM and 1 µM were selected because 2.5 µM already led to a reduction of 
cell mass by 74 %. 
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3.5 Summary of the monotherapeutic treatment 
The table below shows the MOIs of VACV GLV-1h68 and the concentrations of 
the different epigenetic compounds, which were chosen for further experiments. 
Cell lines MOI HDACi  Concentrations 
ACHN 0.01 resveratrol 2.5 µM 
5 µM 
kaempferol 
 
10 µM 
20 µM 
SAHA 1 µM 
2.5 µM 
HCT-15 0.1 resveratrol 10 µM 
20 µM 
kaempferol 10 µM 
20 µM 
SAHA 1 µM 
2.5 µM 
HCT-116 0.01 resveratrol 10 µM 
20 µM 
kaempferol 10 µM 
20 µM 
SAHA 0.5 µM 
1 µM 
Colon-26 0.1 resveratrol 10 µM 
20 µM 
kaempferol 10 µM 
20 µM 
SAHA 1 µM 
2.5 µM 
Table 13. Summary of the concentrations used for combinatorial treatment. 
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3.6 Combination therapy of vaccinia virus GLV-1h68 with epigenetic 
compounds  
With the results from the pre-testing above, combinatorial treatment was 
performed (Figure 19). Tumor cells were plated. After 24 h, cells were treated 
with one of the epigenetic compounds. 24 h later, cells were infected with GLV-
1h68 or mock-infected. 72 hpi, remnant tumor cell masses were quantified in 
different assays.  
 
Figure 19. General application scheme for combinatorial treatment of tumor cell lines 
with the epigenetic compounds and GLV-1h68. 24 hours after cells were plated, treatment 
with one epigenetic compound, resveratrol, kaempferol, or SAHA, was performed. 24 later, cells 
were infected with GLV-1h68 or mock-infected. 72 hours post infection (hpi), different assays 
were performed. 
First, SRB viability assay was performed. The results of the SRB viability assay 
did not measure the expected differences as seen after wells were colored with 
SRB staining solution. To validate the antiproliferative and cytotoxic potential of 
the co-treatment, further cell viability assays were performed, such as CellTiter-
Blue assay, LDH assay, and area calculation, using the dyed wells from SRB 
viability assay. Since these differences were also seen in kaempferol and 
SAHA, same assays were performed as well. For promising co-treatments, 
mainly with resveratrol or SAHA, further assays were performed, e.g. analysis 
of the cell cycle profile, viral replication behavior of GLV-1h68, and cell growth 
over time in the real-time cell monitoring.  
For a better distinction, the blue-colored bars in each graph indicate the 
combinatorial treatments. 
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3.6.1 Combination therapy of vaccinia virus GLV-1h68 and resveratrol 
3.6.1.1 Cell viability and cytotoxicity assays 
SRB assay 
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Figure 20. SRB viability assay and pictures of the 24-well plates. Cells were either treated 
with resveratrol (RV), infected with GLV-1h68 alone or co-treatment was performed. SRB 
viability assay was performed 72 hpi to quantify the remnant tumor cell masses. On the left-
hand side, mean of three independent experiments performed in quadruplicates is shown. Error 
bars indicate +/- SD. The mock-treated quadruplicate was set to 100 % cell mass. The right-
hand side shows the pictures of the 24-well plates after staining with sulforhodamine B dye 
(above), and after solubilization with Tris base (below). One row of the 24-well plate is 
exemplarily shown for one of the three experiments. 
As seen in the graphs of the SRB assays on the left-hand side in Figure 20, 
combinatorial treatment only had a marginal or no benefit in ACHN and HCT-15 
cells when compared to the respective mono-treatments. By contrast, Colon-26 
cell masses were reduced to 78 % in co-treatment with 10 µM resveratrol 
whereas a reduction to 89 % (RV) and 93% (GLV-1h68) was achieved in 
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monotherapy. In HCT-116, cell viability in co-treatment with 10 µM resveratrol 
was reduced to a mean of 78 %, compared to the single treatment 89 % (RV) or 
98 % (GLV-1h68). 
When looking at the pictures of the stained wells on the right-hand side, 
combinatorial treatment in ACHN, HCT-15, and HCT-116 showed more and 
larger plaques than monotherapeutic treatment with GLV-1h68 alone. In Colon-
26 cells, combinatorial treatment resulted in fewer plaques in comparison to 
monotherapy with GLV-1h68 alone, but the cell layer was visibly reduced.  
Mainly in HCT-116 and Colon-26, the pictures of the dyed plates and the 
solubilized dye demonstrated discrepancies. Especially in the last (6th) panel 
(co-treatment with the higher resveratrol concentration), the cell layer was 
visibly reduced when color was dried, but when solubilized with Tris, pink color 
appeared stronger than expected and the measured optical density (OD) didn’t 
show expected outcomes. In contrast, the pictures of the stained wells of ACHN 
plates were in accordance with the analysis of the solubilized dye. To clear 
discrepancies, cell-free area of the wells was calculated (see Figure 24). 
 
CellTiter-Blue assay 
To further validate the antiproliferative potential of the co-treatment with 
resveratrol, the cytotoxicity assay CellTiter-Blue (Figure 21) was performed.  
In HCT-116 cells, the cell viability decreased in combinatorial treatment and 
reached values below the indicated 75 % threshold. In HCT-15 and Colon-26 
cells, a benefit was detectable between monotherapy with resveratrol 
concentrations of 10 µM and combinatorial treatment with 10 µM resveratrol at 
MOI 0.1. In HCT15 cell mass decreased from 85 % in monotherapy (RV alone) 
to 76 % in co-treatment, whereas in Colon-26 cells cell mass decreased from 80 
% (RV alone) to 64 % in co-treatment. At resveratrol concentrations of 20 µM 
no further reduction of cell viability was observed upon additional infection with 
GLV-1h68. In ACHN cells, no benefit could be identified in co-treatment 
compared to single-agent treatment.  
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Figure 21. CellTiter-Blue assay. The four cell lines were either treated with resveratrol (RV) 
alone, infected with GLV-1h68 alone or co-treatment was performed. After 72 hpi, CellTiter-Blue 
assay was performed. Mean of three independent experiments performed in quadruplicates is 
shown. Error bars indicate +/- SD. The mock-treated quadruplicate was set to 100 % cell mass. 
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LDH assay 
In the next step, the LDH assay was performed 120 h after cells were plated 
(Figure 22). It measures the release of LDH into the culture medium after cell 
death. 
 
Figure 22. LDH assay. The four cell lines were either treated with resveratrol (RV) alone, 
infected with GLV-1h68 alone or co-treated. 120 h after seeding, LDH assay was performed. As 
a control for total LDH release, Triton was added to four wells. Mean of three independent 
experiments performed in quadruplicates is shown. Error bars indicate +/- SD. The mock-
treated quadruplicate was set to 100 % LDH activity. 
In all cell lines, combinatorial treatment did not measurably increase LDH 
activity, when compared to the respective mono-treatments.  
 
 
55 
3.6.1.2 Fluorescence monitoring 
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Figure 23. Fluorescence monitoring of the different cell lines in monotherapy with GLV-
1h68 compared to combinatorial treatment with resveratrol (RV). The four cell lines were 
either infected with GLV-1h68 alone or co-treatment with resveratrol was performed. 72 hpi, 
expression of GFP was analyzed by fluorescence microscopy. Serial phase contrast bright-field 
microscopy (BF) and corresponding fluorescence photos (GFP) were taken at the same 
magnification and overlaid. Green fluorescence indicates infection with GLV-1h68. 
At 72 hpi, combinatorial treatment with resveratrol resulted in an increased 
green fluorescence signal when compared to treatment with GLV-1h68 alone in 
ACHN, HCT-15, and HCT-116 cells. In contrast, murine Colon-26 cells showed 
an adverse effect in co-treatment with 20 µM resveratrol - the GFP signal was 
reduced and plaques decreased in number and size. In bright-field (BF) micro-
scopy, the cell mass was visibly reduced in cell lines ACHN and HCT-116, 
whereas in HCT-15, cell mass appeared constant (Figure 23). 
 
The results of the different viability assays, such as SRB assay, CellTiter-Blue 
assay and LDH assay did not visualize expected outcomes as seen after 
detection of GFP in fluorescence microscopy or remaining cells in the wells 
after colored with SRB staining solution. Therefore, the wells were dyed with 
SRB staining solution and photographed. Cell-free area was calculated as seen 
in Figure 24.  
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3.6.1.3 Area calculation 
 
Figure 24. Area calculation. Cells were treated with the chosen concentrations of resveratrol 
(RV). After 24 h, cells were infected with VACV GLV-1h68. After 72 hpi, SRB assay was 
performed. After the 24-well plate was dyed with SRB staining solution and dried overnight, 
area calculation was performed to quantify cell-free area of the wells. The columns of each 
group show the cell-free area in percent. Mean of three independent experiments performed in 
quadruplicates is shown. Error bars indicate +/- SD. 
Compared to treatment with resveratrol or GLV-1h68 alone, combinatorial 
treatment leads in all cell lines to increased cell-free areas and thus displayed 
signs of cell death. Results were promising for co-treatment in HCT-116 cells 
with GLV-1h68 and resveratrol. Here, a cell-free area in the range of 65 - 67 % 
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was achieved, whereas monotherapy with GLV-1h68 alone only reached a cell-
free area of 36 %. In HCT-15, a cell-free area of 31 % was achieved in co-
treatment compared to 7 % (20 µM RV) or 9 % (GLV-1h68 MOI 0.1) in single-
agent treatment. ACHN cells showed a cell-free area in the range of 11 - 13 % 
in co-treatment compared to 3 % in single-agent treatment with 5 µM RV. 
Combinatorial treatment in Colon-26 cells demonstrated a marginal effect at a 
resveratrol concentration of 20 µM. In the lower resveratrol concentration, a 
small benefit could be identified (Figure 24). 
 
Since treatment with ACHN and HCT-116 showed best results with the 
epigenetic compound resveratrol, further investigations were conducted. The 
real-time cellular impedance assay was performed with ACHN and HCT-116 
solely. Virus growth curves were performed with ACHN cells only. 
 
3.6.1.4 Virus growth curves 
ACHN cells were infected with GLV-1h68 at MOI 0.01. Infected cells were 
harvested and frozen at 1, 24, 48, 72 and 96 hpi. Virus titration was performed 
using CV-1 cells to quantify the amount of virus plaques. Replication behavior 
of GLV-1h68 at MOI 0.01 was analyzed via growth curves (chapter 2.9).  
Viral replication started post infection in monotherapy and co-treatment. Viral 
particles increased most strikingly during the first 24 hpi in monotherapy. In the 
following 24 h, virus production stagnated when looking at GLV-1h68 infection 
solely (red line). When looking at the complete detection period, resveratrol did 
not enhance the replication of GLV-1h68 (black line) when compared to 
infection with GLV-1h68 solely (red line) (Figure 25).  
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Figure 25. Replication of GLV-1h68 with or without 5 µM resveratrol (RV) in ACHN cells. 
Cells were treated with resveratrol or mock-treated. After 24 h, cells were infected with GLV-
1h68 at MOI 0.01. At 1, 24, 48, 72 and 96 hpi, samples were taken. Titration was performed on 
CV-1 cells to quantify the amount of virus plaques. The result of solely GLV-1h68-infected cells 
(red line) is displayed along with GLV-1h68 + resveratrol co-treated cells (black line). Results 
are shown in PFU/ml. Mean of three independent experiments is shown. Error bars indicate +/- 
SD. 
 
6.6.1.5 Real-time Cellular Impedance measurement 
The techniques above are different kinds of endpoint assays, which do not 
provide information about the onset of cytopathic effects and kinetics of viral 
replication. In contrast, the real-time cellular impedance measurement monitors 
all cell events during the complete detection period, e.g. cell number change 
and cell viability. 
Based on the dynamic monitoring of cell proliferation, 24 hours after seeding, 
ACHN and HCT-116 cells were treated using different resveratrol 
concentrations and 24 h later infected with GLV-1h68 at MOI 0.01 alone or 
combinatorial treatment was performed. 
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Figure 26. Real-time monitoring of proliferation of ACHN tumor cells after treatment with 
5 µM resveratrol (RV) and infection with GLV-1h68. The colored lines indicate the different 
treatments. Cells were measured every 30 minutes using the RCTA SP instrument. Measured 
electrode impedance is expressed as Cell Index and graphically represented. 
Combinatorial treatment with GLV-1h68 and 5 µM resveratrol (Figure 26, light 
blue line) showed an increased oncolytic cell death in ACHN tumor cells over 
120 h in comparison to mock treatment or monotherapy alone.  
 
 
Figure 27. Real-time monitoring of proliferation of HCT-116 tumor cells after treatment 
with 20 µM resveratrol (RV) and infection with GLV-1h68. The colored lines indicate the 
different treatments. Cells were measured every 30 minutes using the RCTA SP instrument. 
Measured electrode impedance is expressed as Cell Index and graphically represented. 
Experiments with the tumor cell line HCT-116 showed in co-treatment a 
marginal benefit with 20 µM resveratrol (Figure 27, light blue line). 
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3.6.2  Combination therapy of vaccinia virus GLV-1h68 and kaempferol 
3.6.2.1 Cell viability assays 
SRB assay 
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Figure 28. SRB viability assay and pictures of the 24-well plates. Cells were treated with 
the chosen concentrations of kaempferol (KMF). After 24 h, cells were infected with VACV GLV-
1h68. At 72 hpi, SRB assay was performed. On the left-hand side, mean of three independent 
experiments performed in quadruplicates is shown. Error bars indicate +/- SD. The mock-
treated quadruplicate was set to 100 % cell mass. The right-hand side shows the pictures of the 
24-well plates after staining with sulforhodamine B dye (above), and after solubilization with Tris 
base (below). One row of the 24-well plate is exemplarily shown for one of the three 
experiments. 
As seen in the graphs on the left-hand side in Figure 28, combinatorial 
treatment of HCT-15 and HCT-116 tumor cells leads to a slight increased cell 
death compared to monotherapies. Co-treatment with 20 µM kaempferol was 
found to reduce cell mass in HCT-15 cells to 76 % compared to 93 % 
kaempferol (KMF) or 100% (GLV-1h68) in the corresponding monotherapies. 
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Combinatorial treatment in HCT-116 cells led to a reduction of cell mass to 79 
%, whereas the respective mono-treatments reduced cell mass only to a range 
of 91 - 97 %. By contrast, combination therapy had little or no benefit in ACHN 
and Colon-26 cells. As a result, in none of the four analyzed cell lines 
combinatorial treatment could reduce cell mass to significantly less than 70 %. 
When looking at the images on the right-hand side, in panel 1, the mock-treated 
cells showed no cell-free area except for HCT-15 and Colon-26, similar to panel 
two and three with the two different concentrations of kaempferol.  
Plaques were visible in panel four in all cell lines. Combinatorial treatment in 
ACHN, HCT-15, and HCT-116 showed more and larger plaques. In Colon-26 
cells, combinatorial treatment displayed fewer plaques when compared with 
monotherapy GLV-1h68 alone. 
Nevertheless, in all cell lines, dried dye and solubilized dye demonstrated 
discrepancies. Especially for HCT-15 and HCT-116 cells, cell layers were visibly 
reduced in combinatorial treatment; however, when the dye was solved, the 
optical density (OD) was higher than expected. Therefore, cell-free areas of the 
wells were calculated to graphically display the visible increased cell death in 
ACHN, HCT-15, and HCT-116 cells (see Figure 32). 
 
CellTiter-Blue assay  
A slight benefit was observed in combination therapy in Colon-26, HCT-15 and 
HCT-116 cells (see Figure 29). When GLV-1h68 was added to 10 µM 
kaempferol, co-treatment reduced the cell mass from 84 % to 73 % in Colon-26 
cells. Co-treatment with 10 µM kaempferol was found to reduce cell mass in 
HCT-116 cells to 80 % compared to 94 % (KMF) or 81 % (GLV-1h68) in the 
corresponding monotherapies. The cell line ACHN hardly responded to 
combinatorial treatment. 
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Figure 29. CellTiter-Blue assay. The graphs represent the four cell lines, which were either 
treated with kaempferol (KMF) alone, infected with GLV-1h68 alone or co-treatment was 
performed. After 72 hpi, CellTiter-Blue assay was performed to quantify cell viability. Mean of 
three independent experiments performed in quadruplicates is shown. Error bars indicate +/- 
SD. 
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LDH assay 
 
Figure 30. LDH assay. The graphs represent the four cell lines, which were either treated with 
kaempferol (KMF) alone, infected with GLV-1h68 alone or co-treatment was performed. 
Thereafter, LDH assay was performed. As a control for total LDH release, cells were completely 
lysed with Triton. Mean of three independent experiments performed in quadruplicates is 
shown. Error bars indicate +/- SD. The mock-treated quadruplicates were set to 100 % LDH 
activity.  
In ACHN, Colon-26, HCT-15, and HCT-116 cells, combinatorial treatment did 
not measurably increase LDH activity when compared to the respective mono-
treatments. A slight increased LDH activity could be seen in co-treatment in 
HCT-116 cells at a concentration of 20 µM KMF compared to the respective 
mono-treatments (Figure 30). 
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3.6.2.2 Fluorescence monitoring 
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Figure 31. Fluorescence monitoring of the four cell lines in monotherapy with GLV-1h68 
compared to combinatorial treatment with kaempferol (KMF). The four cell lines were either 
infected with GLV-1h68 alone or co-treatment with KMF was performed. After 72 hpi, the 
expression of GFP was analyzed by fluorescence microscopy. Green fluorescence indicated the 
infection of tumor cells. Phase contrast and fluorescence photos were taken and overlaid.  
In ACHN cells, the presence of kaempferol resulted in more and larger plaques. 
Additionally, slightly more green fluorescence was emitted. In HCT-15 and 
HCT-116 cells, combinatorial treatment led to an increased virus-associated 
GFP expression. In HCT-116 cells, at MOI 0.01 and 20 µM kaempferol almost 
every cell was infected. In contrast, murine Colon-26 cells displayed an adverse 
effect in combination therapy when compared to the other cell lines. Less green 
fluorescence as well as fewer plaques were visible in combinatorial treatment 
with kaempferol in comparison to monotherapy. Nevertheless, the cell layer was 
visibly reduced at a concentration of 10 µM kaempferol (Figure 31). 
 
3.6.2.3 Area calculation 
Except for Colon-26, each cell line showed an increased cell-free area in 
combinatorial treatment and thus displayed signs of increased cell death (see 
Figure 32). Co-treatment in ACHN cells achieved a cell-free area in the range of 
13 - 15 % compared to 2 % (GLV-1h68 single-treatment alone). In HCT-15 
cells, cell-free area was found to be further increased to a mean of 40 % in co-
treatment with 20 µM kaempferol compared to 12 % (GLV-1h68) or 6 % 
(kaempferol) in the monotherapeutic approaches. In HCT-116 cells, the 
combination therapy reduced the cell layer further to a range of 59 - 62 % 
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compared to 43 % in single-agent treatment with GLV-1h68. Only Colon-26 
cells showed a decreased cell-free area in combinatorial treatment. 
 
 
Figure 32. Area calculation. Cells were treated with the chosen concentrations of kaempferol 
(KMF). After 24 h, cells were infected with VACV GLV-1h68. After 72 hpi, the cell-free area was 
determined to quantify remnant tumor cell mass. The columns of each group show the cell-free 
area in percent. Mean of three independent experiments performed in quadruplicates is shown. 
Error bars indicate +/- SD.  
 
 
 
69 
3.6.3 Combination therapy of vaccinia virus GLV-1h68 and SAHA  
3.6.3.1 Cell viability and cytotoxicity assays 
SRB assay 
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Figure 33. SRB viability assay and pictures of the 24-well plates. Cells were treated with 
SAHA alone, infected with GLV-1h68 alone or co-treatment was performed. After 72 hpi, SRB 
assay was performed. On the left-hand side, mean of three independent experiments performed 
in quadruplicates is shown. Error bars indicate +/- SD. The mock-treated quadruplicate was set 
to 100 % cell mass. The right-hand side shows the pictures of the 24-well plates after staining 
with sulforhodamine B dye (above) and after solubilization with Tris base (below). One row of 
the 24-well plate is exemplarily shown for one of the three experiments. 
As seen in the graphs on the left-hand side in Figure 33, combinatorial 
treatment of HCT-116 leads to increased tumor cell killing compared to the 
respective mono-treatments. In detail, HCT-116 cell masses were reduced to 62 
% in co-treatment (with 1 µM SAHA) whereas a reduction to only 86 % (1 µM 
SAHA) or 91 % (GLV-1h68) could be achieved in monotherapies. The lower 
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SAHA concentration reduced the cell mass to 72 % in co-treatment compared 
to the respective single-agent treatment with 0.5 µM SAHA alone. In HCT-15 
cells, co-treatment with 2.5 µM SAHA showed also an increased tumor cell 
killing. Cell mass was reduced from 69 % in monotherapy (2.5 µM SAHA) to 56 
% in co-treatment (2.5 µM SAHA with GLV-1h68). In contrast, in ACHN and 
Colon-26 cell lines combination therapy was not superior to monotherapy. 
When looking at the images on the right-hand side in Figure 33, except for 
HCT-15, in panel 1, the mock-treated cells showed no cell-free area, similar to 
panel two and three with the two different concentrations of SAHA. In panel four 
in ACHN, HCT-116, and Colon-26, plaques were visible. Combinatorial 
treatment in ACHN, HCT-15, and HCT-116 showed more and larger plaques. In 
Colon-26 cells, combination therapy displayed fewer plaques than in 
monotherapy with GLV-1h68 alone. 
Nevertheless, when dyed wells were solubilized, previous differences could not 
be displayed. Particularly, in combinatorial treatment in ACHN, HCT-15, and 
HCT-116 cells, cell layer were visibly reduced, but after solubilization of the dye 
the OD was higher. To clear these discrepancies, cell-free areas of the wells 
were calculated (see Figure 38). 
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CellTiter-Blue assay 
As seen in Figure 34, a reduced cancer cell viability was achieved for HCT-116 
cells in combinational treatment (53 %), compared to 1 µM SAHA (71 %) and 
GLV-1h68 (84 %) single-agent treatment. ACHN, HCT-15, and Colon-26 did not 
respond to combinatorial treatment compared to monotherapy. 
 
 
Figure 34. CellTiter-Blue assay. The graphs represent the four cell lines, which were either 
treated with SAHA alone, infected with GLV-1h68 alone or co-treatment was performed. After 
72 hpi, CellTiter-Blue assay was performed. Mean of three independent experiments performed 
in quadruplicates is shown. Error bars indicate +/- SD. 
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LDH assay 
 
Figure 35. LDH assay. The graphs represent the four cell lines, which were either treated with 
SAHA alone, infected with GLV-1h68 alone or co-treatment was performed. Afterwards, LDH 
assay was performed. As a control for total LDH release, cells were completely lysed with 
Triton. Mean of three independent experiments performed in quadruplicates is shown. Error 
bars indicate +/- SD. The mock-treated quadruplicates were set to 100 % LDH activity.  
In ACHN cells, co-treatment with 2.5 µM SAHA led to an increased LDH activity 
(183 %) compared to single-agent treatment with GLV-1h68 alone (118 %). In 
HCT-15, HCT-116, and Colon-26, combination therapy displayed less LDH 
activity in contrast to monotherapy with GLV-1h68 or mock-treatment solely 
(see Figure 35).  
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MTT assay 
Since treatment of ACHN and HCT-116 showed best results with the epigenetic 
compound SAHA, further investigations were conducted. MTT assay, flow 
cytometry and real-time cellular impedance assay were performed solely with 
ACHN and HCT-116 cells. Virus growth curves were performed with ACHN 
cells only. 
 
 
Figure 36. MTT assay. ACHN and HCT-116 cells were either treated with SAHA alone, 
infected with GLV-1h68 alone or co-treatment was performed. After 72 hpi, MTT assay was 
performed. Mean of three independent experiments performed in quadruplicates is shown. Error 
bars indicate +/-SD. The mock-treated quadruplicates were set to 100 % viability.  
Combinatorial treatment showed an improved tumor cell killing in ACHN and 
HCT-116 cells. Especially the higher SAHA concentration in each cell line 
(ACHN 2.5 µM, HCT-116 1 µM) reduced cell viability to 38 % in ACHN cells and 
34 % in HCT-116 cells (Figure 36).  
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3.6.3.2 Fluorescence monitoring 
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Figure 37. Fluorescence monitoring of the four different cell lines either in monotherapy 
with GLV-1h68 alone or in combinatorial treatment with SAHA. The four cell lines were 
either infected with GLV-1h68 alone or co-treatment with SAHA was performed. After 72 hpi, 
expression of GFP was analyzed by fluorescence microscopy. Green fluorescence indicated the 
infection of tumor cells. Phase contrast and fluorescence photos were taken and overlaid. 
At 72 hpi, combinatorial treatment with SAHA resulted in an increased virus-
associated expression of GFP in ACHN, HCT-15, and HCT-116 cells. In Colon-
26 cells, a reduced GPF signal was seen in combinatorial treatment in 
comparison to monotherapy with GLV-1h68 at MOI 0.1. 
 
3.6.3.3 Area calculation 
At 72 hpi, combinatorial treatment with SAHA caused a significant cell mass 
reduction in ACHN, HCT-15, and HCT-116 cells. Using the higher concentration 
of SAHA, ACHN reached almost 40 % cell-free area, in comparison to mono-
therapy with a cell-free area of 2 % (GLV-1h68 alone). Similar results were 
achieved in HCT-15 cells with SAHA 2.5 µM in combinatorial treatment. The 
cell-free area increased from 15 % with 2.5 µM SAHA alone to 43 % in co-
treatment with GLV-1h68. A benefit in combinatorial treatment was visible in 
HCT-116 cells as well. Co-treatment enhanced the cell-free area to 60 – 67 % 
compared to the respective mono-treatment with GLV-1h68 alone (45 %). In 
Colon-26, combinatorial treatment reduced cell mass less than monotherapy 
with GLV-1h68 (Figure 38).  
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Figure 38. Area calculation. 72 hpi after treatment, the cell-free area was determined to 
quantify remnant tumor cell mass. The columns of each group show the cell-free area in 
percent. Mean of three independent experiments performed in quadruplicates is shown. Error 
bars indicate +/- SD.  
 
3.6.3.4 Virus growth curves 
In a next step, the replication behavior of GLV-1h68 at MOI 0.01 in combination 
with SAHA at a concentration of 2.5 µM in ACHN cells was analyzed via growth 
curves. 
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Figure 39. Replication of VACV GLV-1h68 with or without SAHA (2.5 µM) in ACHN cells. 
Cells were treated with SAHA or mock-treated. After 24 h, cells were infected with VACV GLV-
1h68 at MOI 0.01. At 1, 24, 48, 72 and 96 hpi, samples were taken. Titration was performed 
using CV-1 cells to quantify the amount of virus plaques. The result of GLV-1h68 mono-infected 
cells (red line) is displayed along with GLV-1h68 + SAHA co-treated cells (black line). The 
results are shown in PFU/ml. Mean of three independent experiments is shown. Error bars 
indicate +/- SD.  
Replication behavior of GLV-1h68 at MOI 0.01 was analyzed via growth curves. 
Viral replication started post infection in monotherapy and co-treatment. After 24 
hours, virus production stagnated when looking at GLV-1h68 monotherapy (red 
line), whereas virus production slightly increased in co-treatment. Starting at 48 
hpi, SAHA enhanced the replication of GLV-1h68 (black line) compared to 
infection with GLV-1h68 alone (red line).  
 
3.6.3.5 Flow cytometry 
When compared to resveratrol and kaempferol, SAHA seemed to be the most 
promising epigenetic compound. Thus, flow cytometry was performed to 
analyze the cell cycle of ACHN and HCT-116 cells in detail for better 
understanding of growth behavior in co-treatment (Figure 40).  
In ACHN, combinatorial treatment with GLV-1h68 and 2.5 µM SAHA enhanced 
the population of apoptotic cells (black sub2N bar) greatly (37 %) compared to 
combinatorial treatment with 1 µM SAHA (9 %), monotherapy (SAHA or GLV-
1h68, 11 % each) or mock-treated tumor cells only (11 %).  
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In HCT-116, diminishing fractions of apoptotic cells (sub2N) in combinatorial 
treatment or monotherapy with GLV-1h68 were observed (4 - 8 %), alongside 
an enhanced fraction of proliferating cells (characterized by S and G2 phases). 
 
Figure 40. Cell cycle profile of treated ACHN and HCT-116 cells at 72 hpi. Cell lines were 
either mock-treated, or monotherapy with SAHA or GLV-1h68 or co-treatment was performed. 
DNA was stained with propidium iodide (PI) and cells were analyzed by flow cytometry. Mean of 
three independent experiments performed in quadruplicates is shown. Error bars indicate +/- 
SD. 
 
3.6.3.6 Real-time Cellular Impedance measurement 
Based on the dynamic monitoring of cell proliferation, 24 hours after seeding, 
ACHN and HCT-116 cells were treated using different SAHA concentrations 
and 24 h later infected with GLV-1h68 at MOI 0.01 or combinatorial treatment 
was performed. 
 
Figure 41. Real-time monitoring of ACHN tumor cell proliferation after treatment with 
SAHA (2.5 µM) and infection with GLV-1h68. The colored lines indicate the different 
treatments in the E-Plate. Cells were measured every 30 minutes using the RCTA SP 
instrument. Measured electrode impedance is expressed as a Cell Index and graphically 
represented. 
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Combinatorial treatment of the epigenetic compound SAHA with GLV-1h68 
(cyan blue line) showed increased oncolytic cell death when compared to the 
respective mono-treatments (Figure 41).  
 
 
Figure 42. Real-time monitoring of HCT-116 tumor cell proliferation after treatment with 
SAHA (1 µM) and infection with GLV-1h68. Cells were measured every 30 minutes using the 
RCTA SP instrument. Measured electrode impedance is expressed as a Cell Index and 
graphically represented. 
Combinatorial treatment (cyan blue line) showed increased oncolytic cell death 
in HCT-116 tumor cells over 120 h when compared to the respective mono-
treatments.  
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4. Discussion 
Cancer is one of the leading causes of death worldwide. In order to improve 
current cancer treatment modalities, novel therapy options are needed beyond 
the standard approaches such as surgery, chemotherapy and radiotherapy. 
Immunovirotherapy is one of these new alternatives. Because several tumor 
entities show resistances towards virotherapy, combining virotherapy with 
different other agents such as epigenetic modulating compounds, chemo-
therapy or immune checkpoint inhibitors is necessary. Previous studies have 
shown promising results concerning virotherapeutics as well as epigenetic 
compounds, both independently and in combinatorial treatment [43, 44, 151]. 
In this study, a panel of 4 different cell lines, three colorectal cancer cell lines 
and one renal adenocarcinoma cell line, were tested regarding their 
susceptibility to vaccinia virus (VACV) GLV-1h68 infection and to different epi-
genetic compounds, such as resveratrol (RV), kaempferol (KMF) and SAHA, 
both in monotherapy and in co-treatment. 
Depending on dose and length of exposure, monotherapy with GLV-1h68 and 
also the epigenetic compounds killed tumor cells in all 4 cell lines. For 
combinatorial treatment, a low multiplicity of infection (MOI) of GLV-1h68 as 
well as low concentrations for RV, KMF and SAHA were chosen, which reduced 
cell mass by purpose ”only” in the range of 25 %. 
Combinatorial treatment showed a beneficial cytotoxic effect in all cell lines, 
although this effect was minimal in some experiments. The murine cell line 
Colon-26 behaved differently regarding the cytotoxic effects as shown in 
different experiments, e.g., area calculation and fluorescence monitoring 
(3.6.1.2 Fluorescence monitoring and 3.6.1.3 Area calculation). Nevertheless, 
cytotoxic effects varied in all examined cell lines depending on the performed 
method. Further limitations were observable and are mentioned in the 
subsequent parts.  
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Monotherapy with VACV 
Infection with VACV GLV-1h68 was monitored through fluorescence microscopy 
and SRB assay. HCT-15 and Colon-26 were classified as highly resistant and 
therefore a MOI of 0.1 was chosen for further experiments. HCT-116 and ACHN 
were classified as susceptible to GLV-1h68; therefore, a MOI of 0.01 was used 
for combinatorial treatment. The aim was to overcome these resistance profiles 
in co-treatment.  
Depending on the MOI, the different cell lines reacted in various degrees of 
cytotoxicity, virus replication and intensity of GFP marker gene expression, 
which correlate with the reports by Ascierto et al. [152]. 
According to Ehrig et al., HCT-116 cells were highly susceptible to GLV-1h68 at 
MOI 0.1 in vitro as well as in xenograft mouse models. GLV-1h68 efficiently 
infected, replicated in and lysed the human colorectal cancer cell line. 
Treatment with VACV GLV-1h68 was less effective in HCT-15 cells both in vitro 
and in an in vivo mouse model [153]. Of note, these findings correlate with our 
results and the results from C. Raff (MD thesis work also performed in Prof. 
Lauer´s laboratory; submitted for publication) that HCT-116 cells were more 
susceptible to VACV compared to HCT-15. HCT-15, on the other hand was 
classified as a tumor cell line being resistant to VACV GLV-1h68. 
 
The impact of resveratrol on viral replication 
In several previous in vitro and murine in vivo studies, inhibitory effects were 
shown in monotherapy with different resveratrol concentrations starting at 10 
µM. Resveratrol suppresses the growth in multiple tumor entities, and also in 
the tumor cell lines used in this study [154-159]. Nevertheless, results of 
proliferation inhibition as well as induction of apoptosis were strongly dependent 
on the resveratrol concentrations [160].  
In this study, resveratrol concentrations for co-treatment were reduced to 2.5 - 
20 µM compared to the above-mentioned studies, which used concentrations 
up to 100 µM. In this project, which rather aimed at overcoming resistances and 
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inducing apoptosis in low resveratrol concentrations, inhibitory effects were 
diminished. As a general rule, synergistic effects could only be achieved when 
inhibitory effects in monotherapy were subtherapeutic. Additionally, low 
concentrations seemed to be a useful aspect, since high blood levels could not 
be reached in vivo so far due to its fast metabolism [113]. However, in further 
investigations it might be reasonable to use higher resveratrol concentrations 
since Tsunoda et al. observed that 10 µM resveratrol were insufficient for 
inducing apoptosis of HCT-116 cells in monotherapy in vitro [161]. 
New forms of administration include on the one hand a combination with nano-
particles due to an increased stability of resveratrol [162], or on the other hand 
through micronized resveratrol, small particles, which increase the orally 
administered resveratrol into the organism significantly [163]. Alternative 
methods of administration need to be performed and validated to improve the 
bioavailability of resveratrol [164]. 
In previous studies, resveratrol has been shown to inhibit replication of many 
viruses such as influenza or herpes simplex [165, 166]. Last year, Cao et al. 
demonstrated that resveratrol strongly suppresses the replication of a Western 
Reserve VACV strain in various cell types, such as HeLa cells. Therefore, it was 
difficult to predict the impact of resveratrol not only on GLV-1h68 but also on the 
used tumor cell lines in this study.  
Our results demonstrate that co-treatment with resveratrol and GLV-1h68 did 
not lead to significant benefits, which could possibly also be explained by a 
resveratrol-mediated inhibition. Further comparative experiments are necessary 
in order to form a better understanding of the cellular function and molecular 
way of action of VACV [167]. 
Nevertheless, fluorescence microscopy analysis showed in all cell lines, except 
for Colon-26 that combinatorial treatment led to an enhanced GFP signal 
indicating a stronger virus replication compared to VACV monotherapy. As seen 
in Colon-26, less GFP signal as well as less cell-free area in co-treatment could 
be detected when compared to single-agent treatment (3.6.1.2 Fluorescence 
monitoring and 3.6.1.3 Area calculation).  
 
 
84 
When looking directly at virus growth curves, co-treatment in ACHN cells was 
not beneficial, whereas a synergistic effect could be determined in further 
experiments including the real-time cell monitoring xCELLigence and area-
calculation. Consequently, cell mass reduction could not exclusively be 
dependent on virus replication in cells, but also on resveratrol. 
In contrast, the cell line HCT-116 showed promising results in almost every 
experiment; however, no synergistic effect of co-treatment could be detected in 
xCELLigence analysis. This could possibly be explained by the complicated 
methodology of the real-time impedance measurement and the resulting assay 
variations. For example, cells in the peripheral wells of the 96-well plates did not 
reach confluency and cell growth was visibly reduced compared to the centered 
wells. Temperature difference in the instrument reader could be one reason for 
the weaker growth. For more reliable results, a different application scheme 
would be useful. 
Furthermore, minor synergistic effects can be due to low resveratrol 
concentrations and/ or low MOIs, which were chosen for monotherapy. There-
fore, one possible improvement would be to focus on higher concentrations in 
co-treatment in further investigations to see if these adjustments can overcome 
existing resistances. 
According to Ascierto et al., who screened the NCI-60 panel for the 
susceptibility to VACV GLV-1h68, ACHN and HCT-15 cells express low levels 
of GFP compared to HCT-116. This study confirmed these results. In the study 
of Ascierto, MOIs of 0.3 and 0.6 were chosen, which are higher than the MOIs 
used in this study [152]. 
 
The impact of kaempferol on virus replication 
Jamillo-Carmona et al. and Kalyani et al. showed cytotoxic potential and 
induction of apoptosis of kaempferol in colon cancer cell lines, such as HCT-15 
and HCT-116 cells [168, 169]. Song et al. demonstrated many resistances of 
kaempferol towards renal adenocarcinoma cell lines. Nevertheless, they 
demonstrated inhibition of cell growth and induction of cell death in the renal 
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adenocarcinoma cell lines 786-O and 769-P with kaempferol at a concentration 
of 100 µM [170]. 
In this study, kaempferol in monotherapy showed less cytotoxic effects when 
compared to resveratrol or SAHA. When compared to the concentrations used 
by Song et al., in this study low kaempferol concentrations were used with the 
aim of overcoming resistances in tumor cells by co-treatment. Furthermore, the 
required plasma concentration levels of kaempferol could not be reached yet 
because of its poor bioavailability [117]. Zhou et al. illustrated that co-
administration of kaempferol and ethanol by oral gavage enhanced the bio-
availability of kaempferol [171]. 
Co-treatment with kaempferol showed similar results as seen in experiments 
with resveratrol. In different viability assays with HCT-15, HCT-116 and Colon-
26 cells, marginal benefits in co-treatment were visible. In contrast, ACHN cells 
were not susceptible to co-treatment. However, GFP signal intensity increased 
in combinatorial treatment in each cell line except for Colon-26. As already 
described for resveratrol, Colon-26 showed adverse effects in co-treatment with 
a reduced GFP signal. These results were concordant with the cell-free area in 
the wells. Here, Colon-26 had less cell-free area compared to the other cell 
lines. Regarding the antiviral activity of kaempferol, it was shown that 
kaempferol inhibits the replication of various viruses, such as influenza, polio, 
herpes simplex, coronavirus and vaccinia virus [172-176]. In particular, Dave et 
al. and Kumar et al. described that the leaves of cassia tora, which contain 
kaempferol, have an antiviral activity against both Newcastle and vaccinia virus 
(Dave 2010, Kumar 2017). Whether the anti-viral function of kaempferol plays a 
role in this study could not be clarified in detail and has to be investigated in 
further studies. 
  
The impact of SAHA on virus replication 
Compared to the other epigenetic compounds used in this study, SAHA 
seemed to be the most potent epigenetic modulating agent. Already low SAHA 
concentrations strongly reduced cell mass in monotherapy.  
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According to Bressan et al., the colorectal carcinoma cell line HCT-116 seemed 
to be very sensitive to SAHA [177]. Additionally, SAHA was less cytotoxic 
towards healthy colorectal cells [178], and thus might have a therapeutic 
potential for the treatment of colorectal cancer in vivo. Furthermore, SAHA has 
an impact on renal cell carcinoma cell lines in vitro [179] as well as in murine in 
vivo models [180].  
In this thesis, SAHA concentrations of 2.5 and 5 µM were used. Virus growth 
curves and real-time cell monitoring in ACHN cells with a SAHA concentration 
of 2.5 µM showed a successful replication in co-treatment over 96 hpi. Cell 
cycle analysis showed that 2.5 µM SAHA increased the population of apoptotic 
cells (sub-2N fraction) in ACHN cells compared to co-treatment with 1 µM 
SAHA. In HCT-116, after 120 h an increased fraction of S and G2 phase cells 
was observed, indicating a growth arrest at the S/G2 phase transition. 
Accordingly, co-treatment with SAHA has a different effect on colorectal and 
renal carcinoma cell lines. Furthermore, in the different cell viability assays and 
in real-time cell monitoring, HCT-116 cells were susceptible to SAHA and 
resulted in a synergistic benefit. Again, the Colon-26 cell line showed different 
effects when looking at the GFP signal intensity in fluorescence monitoring. 
Thus, the murine cell line seemed to behave differently in all co-treatments with 
the different epigenetic modulating agents (compare RV and KMF). These 
results were confirmed by area calculation. Here, co-treatment had less cell-free 
area. In the other cell lines, co-treatment resulted in a higher cell-free area.  
  
Limitations in this study 
Methodic issues occurred leading to a limitation of validity of the results, such 
as the observation of an incipient therapeutic effect on the end-point of certain 
assays, variations in results depending on cell passage numbers or limited half-
life of LDH assay. 
The cell numbers were determined for cell survival of 120 h in a 24 well plate. In 
a few experiments, such as real-time cell monitoring xCELLigence and growth 
curves, progression beyond 120 h would be an interesting approach due to its 
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great synergistic effect. The initiation of the synergistic effect was detected the 
later the end-point of the experiment the higher. Unfortunately, in the chosen 
setting (Figure 19), progression beyond 120 h was difficult to accomplish, 
because mock-treated cells were already confluent at this time point and thus 
cell growth was inhibited (compare Figure 20, Figure 28, Figure 33). Further-
more, the medium was depleted after 120 h of incubation, which might influence 
the results.  
Passage numbers of the used cell lines also played an important role in this 
study. Low cell passage numbers present the biology of the original tumor. The 
growth behavior changed with increasing cell passages [181]. Thus, passage 
numbers had to be kept low to obtain consistent results. Nevertheless, results 
varied with different passage numbers. After a specific time, different 
characteristics, such as alterations in morphology, genomic abnormalities, 
alterations in proliferation rates, transfection efficiency and changes in protein 
expression can occur. Consequently, reliability and reproducibility of results 
might vary [182]. Norden et al. demonstrated that Colon-26 cells changed their 
behavior in vitro in protein secretion and IL-6 mRNA depending on the storage 
conditions and passage numbers [183]. Therefore, in further investigations it 
would be important to monitor if different cell passages show variances in drug 
efficiencies, which would explain varying results. 
A further problem, which is frequently ignored by the research community is the 
assessment of reliability and accuracy of the used cells and the question if they 
represent their tumor tissues of origin. Often, the reference strain is not known, 
or multiple unknown passage numbers have been performed, which lead to the 
result that cells have little in common with the original reference strain [184, 
185]. At these conditions, in this study, we tried to stay as close as possible to 
the origin passage number and thus decided to keep the cell passage numbers 
below 20.  
Further limitations could be identified in viability assays, such as the LDH assay. 
The LDH assay measures the activity of marker enzymes that leak out of dead 
cells into the culture medium. LDH, which is released from cells into the 
medium, has a half-life of approximately 9 h. Thus, the assay mostly reflects the 
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last 9 hours of the experiment instead of the total amount of LDH release of the 
whole experiment. It might therefore underestimate the quantity of the absolute 
level of cytotoxicity [186]. In this thesis, the enzyme release varied in the three 
experiments, which were independently performed. In further investigations, 
LDH enzyme activity should be measured at different time points for more 
reliable results. 
 
Current preclinical and clinical studies with VACV, HDACi and different 
co-treatment options 
Lately, oncolytic virotherapy has resulted in promising treatment options for 
various cancer entities. First clinical trials in Phase I/II for the anticancer vaccine 
GL-ONC1 (proprietary name of GMP-derived material of GLV-1h68) are 
currently under investigation to treat solid tumors. Results from first clinical trials 
showed that GL-ONC1 was well-tolerated with low cytotoxicity and successfully 
entered the tumor sites when applied intraperitoneally in patients with peritoneal 
carcinomatosis [187]. Further ongoing clinical trials for ovarian cancer 
(NCT02759588) and malignant pleura effusion (NCT01766739) are in progress 
[188]. When looking at the current progress in epigenetic cancer therapy, SAHA 
(Zolinza®) is already approved by U.S. FDA for the treatment of cutaneous T-
cell lymphoma. Furthermore, multiple studies have been performed for the 
treatment of glioblastoma multiforme, myelodysplastic syndromes and NSCLC 
[129, 132, 189]. 
Regarding co-treatment with VACV and HDACi it was shown that several 
HDACi enhance the susceptibility of tumor cells to VACV killing and thus 
increase OV therapy by suppressing the IFN-mediated pathway. Consequently, 
the tumor selectivity for the oncolytic virotherapy is increased. Furthermore, the 
efficiency of viral replication is enhanced, and the negative effect of the innate 
immunity is lessened [190]. So far, different in vitro experiments of co-treatment 
with oncolytic viruses and HDACi have been performed [44]. MacTavish et al. 
addressed the impact of the oncolytic vaccinia virus JX-594 (Pexa-Vec®) and 
Trichostatin A (TSA) co-treatment in various tumor cell lines. TSA was found to 
enhance the replication of VACV in several cancer cell lines in vivo in nude 
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mice, such as the human colon carcinoma cell line HCT-116, as well as murine 
breast cancer and melanoma cells. Furthermore, significantly fewer lung 
metastases were found after TSA and VACV co-treatment in murine in vivo 
models [43]. 
A literature research of different co-treatment options with HDACi and other 
virus types revealed that VSV and HDACi (TSA) co-treatment resulted in 
increased susceptibility of VSV in vitro and in vivo in nude mice in breast cancer 
[191], in VSV-infected hepatocellular carcinomas [192], as well as in prostate 
cancer [193]. 
Otsuki et al. showed the impact of HSV and HDACi (TSA, VPA) co-treatment in 
human glioblastoma cell lines [194, 195]. Cody et al. demonstrated that HSV 
and HDACi co-treatment led to increased HSV replication in breast cancer cells 
[196].  
According to Ruf et al., co-treatment with oncolytic measles vaccine virus and 
resminostat resulted in enhanced efficacy in hepatocellular carcinoma cell lines 
compared to monotherapy [151]. 
 
Different co-treatment options with VACV 
The co-treatment of oncolytic viruses with chemotherapy is an alternative 
combination scheme to eliminate cancer cells [42]. Multiple oncolytic viruses 
have been combined with different chemotherapy medications and have shown 
to be a more efficient way to improve cancer treatment [197]. Tumor regression 
was seen in co-treatment with the vaccinia virus strain Western Reserve (WR) 
with 5-FC/CD system (suicide gene therapy of the cytosine deaminase (CD) 
gene and 5-fluorocytosine (5-FC)) in an in vivo mouse model [41]. Foloppe et al. 
demonstrated the effective potentiation of oncolytic efficiency by co-treatment of 
VACV with fluorouracil (5-FU) in human colon cancer cell lines in vitro and in 
vivo in a murine model [198]. Yu et al. showed in a mouse model that co-
treatment of VACV GLV-1h68 with cisplatin/gemcitabine enhanced therapeutic 
results in pancreatic cancer compared to single-agent use [199].  
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In addition, oncolytic viruses enhance the effect of immune check point 
inhibitors on tumor cells. The effectiveness of immune checkpoint inhibitors 
might be enhanced by oncolytic viruses, which initiate an immune system attack 
on cancer cells. Two animal studies have been performed so far [200, 201]. T 
cells recognize cancer cells by altered surface properties (antigens). Infection 
with oncolytic viruses can further increase the number of these antigens. 
Virotherapy destroys cancer cells and multiple antigens are released, which on 
their part increase the immune activity. Bourgeois-Daigneault et al. addressed 
the impact of OV to immune checkpoint blockade in refractory triple-negative 
breast cancer. After intravenous infusion, the virus was able to reach all 
metastases and the tumor was eliminated in 20-30% by the OV Maraba MG1 
solely. Combinatorial treatment with the immune check-point-inhibitor PD-1 
increased the remission rate to 60-90% [200]. Thus, combinatorial treatment 
seems to be a promising therapy option for advanced cancer. 
 
Further investigations 
Different application schemes were performed with other co-treatments such as 
HSV and VPA. Results depended on the timing of the epigenetic treatment 
[202]: Whereas the onset of epigenetic treatment before viral infection led to 
improved tumor cell killing, simultaneous treatment decreased viral 
susceptibility [194]. Pretreatment with HDACi arrested the cell cycle in G1 and 
increased HSV-1 replication. In contrast, co-administration weakened the virus 
replication [203]. 
The application scheme used in this study is based on the above-mentioned 
studies. In further investigations, different application schemes such as pulsed 
application of epigenetic compounds could help to improve co-treatment and 
support further decreases of tumor cell growth. Since resveratrol and 
kaempferol are naturally occurring compounds, a daily application could be 
performed to keep bioavailability at a constant level. 
HDACi impair the transcriptional activation of the interferon-mediated pathway 
and thus interfere with the antiviral response in tumor cell lines [190]. This 
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induction of immunostimulatory effects being triggered by the epigenetic 
compound could lead to further improved cytotoxic effects in cancer patients. 
Consequently, it provides a perfect combinatorial treatment to overcome 
resistances in OV therapy in different cancer entities. These findings may have 
an enormous translational potential for treatment of human colorectal and/or 
renal carcinomas as well as other solid tumors and has to be tested in 
forthcoming virotherapeutic clinical trials. 
 
 
 
 
 
92 
5. Summary 
Cancer is one of the leading causes of death worldwide. In order to improve 
current cancer treatment modalities, the development of new therapy options for 
cancer is an important and necessary task of current medical research. 
Oncolytic viruses represent a promising strategy for cancer treatment (so-called 
virotherapy). Oncolytic viruses are capable of selectively infecting, replicating 
within and killing tumor cells with moderate toxicity for healthy non-malignant 
tissues. However, primary resistances of tumor cells against all the available 
virotherapeutics, which are mainly used in monotherapy, limit the efficiency of 
virus-induced oncolysis. Thus, there is a clinical need to accurately characterize 
these viral resistance phenomena and to find ways to efficiently overcome 
them. Because of the impact on inducing cancer cell death and inhibition of 
tumor proliferation, histone deacetylase inhibitors (HDACi) are interesting 
combination partners for new therapy options and might be a key to overcome 
current high-grade tumor cell resistance to virotherapy. Previous studies have 
shown promising results concerning virotherapeutics as well as epigenetic 
compounds, both independently and in combinatorial treatment. 
The aim of this thesis was to establish a combined application scheme of 
vaccinia virus GLV-1h68 and distinct HDACi compounds, such as resveratrol, 
kaempferol (both natural compounds) or SAHA (suberylanilide hydroxamic acid, 
an FDA approved non-natural/chemical HDACi agent) on a panel of four 
different human cell lines, i.e., three colorectal cancer cell lines and one renal 
adenocarcinoma cell line. A further aim was to determine whether the above 
mentioned HDACi compounds can enhance the potency of VACV GLV-1h68 in 
infection-resistant cancer cell lines.  
After having determined suitable concentrations of each agent in a pre-testing 
phase, next cell viability, tumor cell proliferation and oncolytic effects were 
analyzed in co-treatment by viability assays (sulforhodamin B, CellTiter-Blue), 
quantification of lactate dehydrogenase (LDH) release, as well as by real time 
monitoring of tumor cell growth. To further evaluate possible effects on viral 
replication, virus growth curves were performed. Finally, also cell cycle analysis, 
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area calculation of the cell coverage of the surface of the culture wells and a 
comprehensive fluorescence microscopy analysis were determined. 
 
Our results indicate that co-treatment of HDACi compounds with vaccinia virus 
GLV-1h68 causes a moderate increase of cytotoxic effects compared to the 
respective single-agent treatments in all cell lines. In addition, co-treatment 
resulted in an increased virus-associated expression of GFP in ACHN, HCT-15 
and HCT-116 cells when compared to the treatment with GLV-1h68 alone. 
Nevertheless, cytotoxic effects varied in all examined cell lines depending on 
the performed method. 
The murine cell line Colon-26 behaved adverse regarding the virus-associated 
expression/cytotoxic effects as presented in different experiments, e.g., area 
calculation and fluorescence monitoring. Here, further investigations need to be 
performed to identify reasons for the above-mentioned effects. Furthermore, 
SAHA seemed to be the most potent epigenetic compound when compared to 
the other epigenetic compounds used in this study.  
In conclusion, our data show that epigenetic compounds, such as resveratrol, 
kaempferol and SAHA are able to further enhance the potency of VACV GLV1-
h68 in partially or highly resistant tumor cell lines when compared to either of 
the monotherapeutic approaches. Induction of immunostimulatory effects being 
triggered by the epigenetic compound could lead to further improved cytotoxic 
effects in cancer patients. These findings may have an enormous translational 
potential for treatment of human colorectal and/or renal carcinomas as well as 
other solid tumors and have to be tested in forthcoming virotherapeutic clinical 
trials [142]. 
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Zusammenfassung 
Krebs ist eine der häufigsten Todesursachen weltweit. Um die derzeitigen 
Möglichkeiten der Krebsbehandlung zu verbessern, ist die Entwicklung neuer 
Therapieoptionen für Krebs eine wichtige und notwendige Aufgabe der 
aktuellen Forschung. Der Einsatz von onkolytischen Viren stellt eine 
vielversprechende Strategie zur Krebsbehandlung dar (sog. Virotherapie). Bei 
gleichzeitig mäßiger Toxizität gegenüber gesundem, nicht-malignem Gewebe 
sind onkolytische Viren in der Lage, Tumorzellen selektiv zu infizieren, sich 
darin zu replizieren und schließlich diese abzutöten. Primäre Resistenzen von 
Tumorzellen gegen die verfügbaren Virotherapeutika, die hauptsächlich in der 
Monotherapie eingesetzt werden, begrenzen jedoch die Effizienz der 
virusinduzierten Onkolyse. Daher besteht ein hoher klinischer Bedarf, diese 
virotherapeutischen Resistenzphänomene genauer zu charakterisieren und 
somit Wege zu finden, diese in effizienter Weise zu überwinden. Wegen des 
Einflusses auf die Induktion von Krebszelltod und Hemmung der 
Tumorproliferation sind Histon Deacetylase-Inhibitoren (HDACi) interessante 
Kombinationspartner für neue Therapieoptionen und könnten ein Schlüssel zur 
Überwindung der gegenwärtigen hochgradigen Tumorzellresistenzen gegen die 
derzeit verfügbaren Virotherapeutika sein. Frühere Studien haben 
vielversprechende Ergebnisse in Bezug auf Virotherapeutika als auch auf 
epigenetische Wirkstoffe gezeigt, sowohl in Mono- als auch in 
Kombinationstherapie. 
Das Ziel dieser Arbeit war es, ein kombiniertes Anwendungsschema von 
Vaccinia Virus GLV-1h68 und verschiedenen HDACi-Wirkstoffen wie 
Resveratrol, Kaempferol (beides Naturstoffe) oder SAHA (Suberylanilid 
Hydroxamsäure, ein von der FDA zugelassener HDACi-Wirkstoff) an vier 
verschiedenen Karzinomzelllinien, drei kolorektalen und einer 
Nierenadenokarzinomzelllinie, zu erarbeiten. Ein weiteres Ziel bestand darin, zu 
bestimmen, ob die oben genannten HDACi-Verbindungen die Wirksamkeit von 
VACV GLV-1h68 in infektionsresistenten Krebszelllinien erhöhen können. 
Geeignete Konzentrationen jedes Wirkstoffs wurden nun in einem Vortest 
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bestimmt. Anschließend wurden die Viabilität der Zellen, die 
Tumorzellproliferation und die onkolytischen Effekte in einer 
Kombinationsbehandlung durch Viabilitäts-Assays (Sulforhodamin B und 
CellTiter-Blue), Quantifizierung der Freisetzung von Lactatdehydrogenase 
(LDH) sowie durch Echtzeitüberwachung des Tumorzellwachstums analysiert. 
Um mögliche Auswirkungen auf die Virusreplikation genauer zu untersuchen, 
wurden Viruswachstumskurven durchgeführt. Schließlich wurden auch die 
Zellzyklusanalyse, die Flächenberechnung der Wells und eine umfassende 
Fluoreszenzmikroskopie durchgeführt. 
 
Unsere Ergebnisse zeigen, dass die gleichzeitige Behandlung von HDACi-Wirk-
stoffen mit dem Impfvirus GLV-1h68 einen moderaten Anstieg der 
zytotoxischen Wirkungen im Vergleich zu den jeweiligen Monotherapie-
Behandlungen in allen untersuchten Zelllinien bewirkte. Verglichen mit der 
alleinigen Behandlung mit GLV-1h68, führte die Kombinationstherapie zu einer 
erhöhten Virus-assoziierten Expression von GFP in ACHN-, HCT-15- und HCT-
116-Zellen. Dennoch variierten die zytotoxischen Effekte in allen untersuchten 
Zelllinien in Abhängigkeit von der durchgeführten Methode. 
Die murine Zelllinie Colon-26 verhielt sich in Bezug auf die Virus-assoziierte 
Expression / cytotoxische Wirkung, wie sie in verschiedenen Experimenten, z. 
B. Flächenberechnung und Fluoreszenzüberwachung, dargestellt wurde, 
entgegengesetzt. Hier sollten weitere Untersuchungen durchgeführt werden, 
um die Ursache für die oben genannten Effekte zu identifizieren. Darüber 
hinaus zeigte sich in dieser Studie der Wirkstoff SAHA im Vergleich zu den 
anderen epigenetischen Wirkstoffen als am effektivsten. 
Zusammenfassend zeigen unsere Daten, dass epigenetische Wirkstoffe wie 
Resveratrol, Kaempferol und SAHA in der Lage sind, die Wirksamkeit von 
VACV GLV1-h68 in teilweise oder hochgradig resistenten Tumorzelllinien im 
Vergleich zu jedem der monotherapeutischen Ansätze weiter zu erhöhen. Die 
Induktion immunstimulierender Effekte durch die epigenetischen Wirkstoffe 
könnte zu einer weiteren Verbesserung der zytotoxischen Wirkung bei 
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Krebspatienten führen. Diese Befunde können ein enormes klinisches Potential 
für die Behandlung von humanen Kolorektal- und / oder Nierenzellkarzinomen 
sowie anderen soliden Tumoren haben und sollten in zukünftigen klinischen 
Studien weiter getestet werden. 
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6. Index of Abbreviations 
ACHN Renal Cell Carcinoma cell line 
BF Bright-field microscopy 
BFGF Basic fibroblast growth factor 
CD8+ T cells Cytotoxic T lymphocyte 
CI Cell index 
CMC Carboxymethyl cellulose 
CO2 Carbon dioxide 
Colon-26  Colon adenocarcinoma cell line 
CpG Cytosine-guanosine dinucleotide sites 
CRC Colorectal cancer 
CV-1 African green monkey kidney fibroblast cell line 
ddH2O Double-destilled water 
DMEM Dulbecco’s modified Eagle medium 
DMEM-10 DMEM supplemented with 10 % FBS 
DMEM-2 DMEM supplemented with 2 % FBS 
DMSO Dimethylesulfoxide 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferases 
EDTA-
trypsin 
Ethylendiamintetraacetatic acid-trypsin 
EEV Extracellular enveloped virus 
EGFR Epidermal growth factor receptor 
FACS Fluorescence Activated Cell Sorting 
FBS Fetal bovine serum 
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FDA US Food and Drug Administration (FDA) 
g gram 
GFP Green fluorescent protein 
GLV-1h68 Vaccinia vaccine virus 
GL-ONC1 proprietary name of GMP-derived material of GLV-1h68 
h Hour(s) 
H2O Water 
HAT Histone acetyltransferases 
HCl Hydrogen chloride 
HCT-116 Colon carcinoma cell line 
HCT-15 Colon adenocarcinoma cell line 
HDAC Histone deacetylases 
HDACi Histone deacetylase inhibitor(s) 
HIF1-a Hypoxia-inducible factor 1-alpha 
HIV Human immunodeficiency virus 
hpi Hours post infection 
HSV Herpes simplex virus 
IFN Interferon 
IL-6 Interleukin 6 
KMF Kaempferol 
kbp Kilo-base pair 
lacZ Gene that encodes for b-galactosidase 
LDH Lactate dehydrogenase 
LIVP Lister strain from the Institute for Research on Viral 
Preparations 
 
 
99 
MDR-1 Multidrug resistance protein-1 
mg Milligram 
ml Milliliter 
mM Millimolar 
MOI Multiplicity of infection 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NAD+ Nicotinamide adenine dinucleotide ox 
NADH Nicotinamide adenine dinucleotide red 
NCI US National Cancer Institute 
NF-kB Nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells 
NK cells Natural killer cells 
nm nanometer 
NSCLC Non-small-cell lung carcinoma 
OD Optical density 
OV Oncolytic virotherapy 
PBS Dulbecco’s phosphate buffered saline 
PD-1 Programmed cell death protein 1 
PFU Plaque forming units 
PI Propidium iodide 
png  Portable network graphics 
RCC Renal cell carcinoma 
RV Resveratrol 
RNA Ribonucleic acid 
RNAse Ribonuclease 
rpm Rounds per minute 
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RT Room temperature 
RUC-GFP Renilla Luciferase green fluorescent protein fusion gene 
SAHA Suberanilide hydroxamic acid 
SD Standard deviation 
Sir2 Silent information regulator 2 
SRB Sulforhodamine B 
TCA Trichloroacetic acid 
tk thymidine kinase 
TRIS Trishydroxymethylaminomethane 
Triton X-100 Nonionic detergent  
TSA Trichostatin A 
U/I Units/liter 
UV Ultra violet 
v/v Volume per volume 
VACV Vaccinia virus 
VEGF Vascular endothelial growth factor 
VPA Valproic acid 
VSV Vesicular stomatitis Indiana virus 
w/v Weight per volume 
WHO World Health Organization 
WR Western Reserve 
° C Degree Celsius 
µM micromolar 
5-FU fluorouracil 
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